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Abstract 
Autosomal dominantly inherited mutations in the folliculin (FLCN) gene lead to Birt-Hogg-
Dubé syndrome (BHD), which is associated with increased risk of kidney cancer. With the 
aim of better understanding and treating BHD and its associated renal cell carcinoma (RCC) 
this study analyzes the potential use of tumour growth inhibitors selective for FLCN-defective 
cells. Fifteen compounds have been initially selected using the COMPARE algorithm from 
the chemotherapeutic compounds tested in the NCI-60 cell lines panel based on the highest 
toxicity in the cell lines with low level of FLCN expression.  Growth inhibition assays 
performed in a paired RCC cell lines with and without active FLCN confirmed that seven 
compounds decreased growth in FLCN-null cells compared with FLCN-wt cells. The greatest 
inhibitory selectivity was induced by mithramycin in which a 10-fold difference between 
GI50 values in FLCN negative and positive UOK257 cells. Mithramycin was also shown to 
be more cytotoxic to FLCN negative cells than to FLCN-positive UOK257 cells by 10 fold (at 
200nM), in clonogenic survival assays. Low doses of rapamycin (1 nM) further increased 
mithramycin's inhibitory selectivity for FLCN mutant UOK cells, encouraging further 
investigation of mithramycin as a molecularly-targeted therapy for RCC in BHD. 
Investigation into potential synthetic-lethal targets for FLCN found that SSH2 (a Slingshot 
family member implicated in actin reorganization) represents a potential therapeutic target for 
the development of agents to treat BHD as cell death in FLCN-null cells can be triggered by 
SSH2 knockdown. SSH2 siRNA knockdown in FLCN-null cells was associated with 
dysregulated cofilin de/phosphorylation pathways and a reduction in clonogenic survival.  
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Chapter 1: Introduction 
Kidney Cancer 
Cancer is defined by the Oxford English Dictionary as a malignant growth or tumour resulting 
from an uncontrolled division of cells. The in balance of cell proliferation, differentiation and 
cell death is disturbed by failure of cells to die, failure of cells to stop dividing, or abnormally 
increased cell division. It is not one disease, but a group of diseases sharing characteristics of 
uncontrolled growth and invasion to other tissues (metastasis) threatening the life of the 
sufferer. It is a common cause of death throughout the world. In the United States of America, 
cancer is responsible for 22% of deaths (R. J. B. King, 2000). Data from the Vital Statistics of 
Japan showed that total years of life lost due to all cancers were 1,818,960.4 years in 1995 
and 2,160,706.5 years in 2005, corresponding to average years of life lost for all cancer 
combined of 17.6 and 16.7 years (Pham et al. 2010). Increasing understanding of the disease, 
its causes, progression, behaviour and characteristics can have a great benefit to a large 
number of people. 
Kidney cancer caused the deaths of 12,890 people and affected 51,190 people in the USA in 
2007, accounting for about 3.5% of all cancer diagnoses (Jemal et al. 2006) and Kidney 
cancer accounts for almost 40% of deaths from metastases (Murakami et al. 2007). 
In the UK, 9286 new cases of kidney cancer were diagnosed in 2009 for the UK alone. 39% 
(3580) of these were in women and 61% (5706) in men, adding up to approximately 3% of 
the new diagnoses for this year and making it the eighth most frequent cancer in the UK. It 
was the ninth most frequent cancer among British females and the sixth most frequent cancer 
in British males at that time (Cancer Research UK, 2013) and it is still a significant cause of 
death. 
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Fig 1:1993-2009 European Age-Standardised Incidence Rates of Kidney Cancer in the UK. 
European kidney cancer occurrences had increased to more than double the 1975-1977 rates 
by 2007-2009 (Fig 1) and correspondingly, in the UK rates of kidney cancer occurrence have 
gradually grown since the mid-1970s. By 2010 the lifetime risk of developing kidney cancer 
for British females was 1 in 90 and for British males was 1 in 56. This is believed to be due to 
an increased occurrence of risk factors such as obesity and smoking. (Cancer Research UK, 
2013) 
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Fig 2: Ten-Year Relative Survival Rates for Kidney Cancer for England 1996 to 2003 & 
England and Wales 1971-1995 and Predicted 2007 
Fig 2 shows the relative increase in rates of survival for ten-years from diagnosis, in both 
males and females diagnosed with kidney cancer. In England it was thought to be about 43% 
for 2007, increased from 25% in England and Wales during 1971-1975. Kidney cancer 
treatment, as with most cancers, has a higher efficacy if it is diagnosed at an early stage but 
for kidney cancer 24% of cases are emergency presentations (Cancer Research UK, 2013). 
Advanced renal cell carcinoma is highly variable in its course, ranging from disease 
progression with chemotherapy resistance to spontaneous remission. Renal cell cancer is 
rarely curable if it has undergone metastasis at the time of diagnosis and is known to be 
resistant to conventional chemotherapy (Coppin et al. 2005). Distant metastases develop in 
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about one third of patients (Hudes et al. 2007). For patients with metastatic renal-cell 
carcinoma less than 10% 5-year survival rate has been seen (Escudier et al. 2007). As only 
10–15% of such patients respond to currently available single chemotherapy drugs with a 
reduction in tumor growth, conventional systemic chemotherapy agents have not been 
deemed effective in these cases, (Cancer connect). For this reason such conventional systemic 
chemotherapy agents have not played a large role in the treatment of advanced kidney 
cancers.  
 As there are few effective chemotherapeutic options for metastasised kidney cancer, many 
patients die from the disease within 5 years of the diagnosis of metastasised disease. The 
survival has a median of about 10 months (Motzer et al. 1999) and there is only a 10% five 
year survival rate (Cancer Research UK, 2013). (Newer targeted therapies and 
immunotherapy offer better outcomes, but it is obvious that there is a need for improved 
understanding of the disease and better novel treatments to improve the survival rate.  
Hopes have been held for improved outcomes from immunotherapy for some time based on 
the observation that these renal cell carcinoma tumours can occasionally shrink without 
therapy, especially when spread to the lungs, suggesting that immune system-based 
approaches to drug development and treatment might be useful. Immunotherapy works by 
stimulating the immune system to fight the cancer. The two most frequently used types of 
immunotherapy are interleukin-2 (IL-2) and interferon-alfa. In 2008, IL-2 and interferon were 
still the only therapies associated with complete long-term remission. Of the fully validated 
therapies, nephrectomy, followed by interferon-alfa, was thought to be the best strategy for 
survival for fit patients with metastases at diagnosis and minimal symptoms, with interferon-
alfa being shown to give a small survival benefit compared to other commonly used 
treatments (Coppin et al. 2008).  
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As the most common treatments for renal-cell carcinoma that has undergone metastasis, 
interferon-alfa and IL-2, alone or in combination, have been shown to result in a median 
survival of 12.0 to 17.5 months. As they show substantial toxicity and limited efficacy, these 
cytokines rarely benefit patients with adverse prognostic factors or an extensive tumour 
burden. These patients have a lower median survival of 4 to 8 months (Hudes et al. 2007). 
Interferon is a stimulant of the immune system and is produced by the body naturally. 
Interferon-alfa is a laboratory produced compound that mimics the mode of action of 
endogenous interferon. It brings about stimulation to the immune system and recognition and 
destruction of some types of cancer cells (Cancer connect).  However, in advanced renal cell 
cancer, this treatment has a poor prognosis with anticancer responses (reduction of tumor size 
or tumor growth) in fewer than 15 % of patients. It can also give rise to severe side effects 
and, coupled with the lack of evidence for improvement of survival, interferon-alfa use on its 
own remains controversial for renal cell carcinoma treatment (Cancer connect).  
Interleukin-2 (also known as Proleukin) was the standard of care for patients with renal cell 
cancer before the new targeted therapies gained official approval. It is usually given as an 
inpatient treatment at high doses and has historically been linked with side effects that were 
quite severe. The safety of interleukin-2 at high-dose has improved significantly over the past 
ten years however (Cancer connect).   
Unfortunately, the results of long-term clinical trials have given indications of low response 
rates to this treatment. Only about 15% of advanced renal cell carcinoma patients showed an 
anticancer response after high-dose interleukin-2 treatments (Fyfe et al. 1995). This is the 
reason why the combination of interleukin-2 plus targeted therapy is now being studied in 
clinical trials (Cancer connect). It has been shown that high dose interleukin-2 can give 
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equivalent survival to a combination of low dose interleukin-2 plus interferon-alfa, a 
combination known to have greater toxicity than interferon-alfa alone (Coppin et al. 2008). 
As interferon alfa only gives a modest increase in survival, and treatment with high-dose 
interleukin-2 infrequently brings about a complete and lasting response, the need for novel 
treatments is clear. Until recently, there have been no other treatments for RCC patients who 
cannot tolerate these cytokines or are ineligible for these treatments (Escudier, 2007). 
A targeted therapy is one that is specifically designed to minimize damage to healthy, normal 
cells, killing just the cancerous cells. Cancer treatments that “target” cancer cells may have 
advantages including improved outcomes for patients and fewer side effects from the 
treatment. 
Sorafenib (also known as Nexavar) is a multi-kinase inhibitor that is orally active. It has 
tumor angiogenesis and tumour-cell proliferation effects. Identified in the first instance as an 
inhibitor of Raf kinase, sorafenib was shown to inhibit c-Kit protein (c-Kit); vascular 
endothelial growth factor receptors (VEGFR) 1, 2, and 3; FMS-like tyrosine kinase 3 (Flt-3); 
platelet-derived growth factor receptor β (PDGFRβ); and RET receptor tyrosine kinases as  
well. A placebo was compared to sorafenib in a Phase III clinical trial in over 900 advanced 
renal cell cancer patients who had been previously treated. The sorafenib treatment gave 
significant improvement with regard to progression-free survival. 5.5 months progression-free 
survival was seen for those given sorafenib treatment compared with a progression-free 
survival time of 2.8 months for those patients who were given a placebo (Escudier, 2007).  
Sunitinib (also known as Sutent) is a multi-targeted oral inhibitor of tyrosine kinase that 
targets VEGF and PDGF receptors - proteins shown to be responsible for stimulating the 
growth of cancer cells. As second-line treatment in metastatic RCC anti-tumour activity of 
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Sunitinib has been shown. This is a setting in which until this point no other systemic therapy 
had been found effective. About 40% of recurrent renal cell cancer patients in trials were 
shown to have responded to treatment with Sutent, and for three months after treatment about 
one in four patients experienced stable disease. RCC genetics and positive clinical trial results 
such as these indicate that VEGF and PDGF receptor-mediated signalling appears to be an 
effective target for therapy in RCC (Motzer, 2006).  
Temsirolimus (CCI-779, also known as Torisel) is a specific inhibitor of the mammalian 
target of rapamycin kinase (mTOR kinase), which is an intracellular signalling pathway 
component involved in the response of cells to hypoxic stress, their proliferation and growth. 
Temsirolimus forms a complex that inhibits mTOR signaling by binding to FKBP-12 (an 
abundant intracellular protein). The disruption of the mTOR signaling pathway suppresses 
protein production for factors that regulate angiogenesis and cell cycle progression. As 
unregulated angiogenesis is prominent in renal-cell carcinoma, the inhibition of angiogenesis 
by temsirolimus is clinically relevant and may benefit patients with RCC (Hudes et al. 2007).  
626 patients with poor prognosis metastatic RCC who had not received prior therapy were 
treated with either temsirolimus, interferon alfa, or a combination of temsirolimus plus 
interferon-alfa .The addition of temsirolimus to interferon in combination was not shown to 
improve survival. Temsirolimus, when compared with interferon-alfa, gave an overall 
improved survival among patients with metastatic renal-cell carcinoma and a poor prognosis. 
(Hudes et al. 2007) 
Pazopanib (also known as Votrient) targets vascular endothelial growth factor receptor, c-Kit, 
and platelet-derived growth factor receptor working as an oral angiogenesis inhibitor. By 
blocking angiogenesis, the drug has the effect of depriving the tumour of oxygen and 
nutrients causing growth inhibition.  In clinical trials, 435 patients were treated for advanced 
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and/or metastatic RCC, 54% (233) had been given no previous treatment and 46% (202) had 
been previously given cytokine treatments. Pazopanib significantly prolonged the 
progression-free survival time of these patients compared with placebo in the overall study, 
with a median progression-free survival time of 9.2 months as compared to 4.2 months for the 
placebo control group. The objective response rate was 3% with placebo compared to 30% for 
pazopanib and the duration of response had a median of greater than one year. However, side-
effects were recorded including vomiting, diarrhoea, pain, high blood pressure and others 
(Sternberg et al. 2010). 
The humanised monoclonal antibody anti-VEGF, bevacizumab (also known as Avastin) is 
used as targeted therapy that works by inhibition of the vascular endothelial growth factor 
protein known as VEGF. VEGF has a key role in blood vessels’ development. By blocking 
VEGF, bevacizumab affects angiogenesis, depriving the tumour of oxygen and nutrients and 
inhibiting its growth. For patients with metastatic kidney cancer, treatment with a 
combination of bevacizumab and interferon alfa results in a longer time to cancer progression 
than treatment with interferon alpha alone (Escudier et al. 2007). 
10 
 
 
 
 
Fig 3: Diagram of the kidney anatomy  
Kidney cancer itself is not a single disease. There are a number of different types of kidney 
cancer with different clinical courses, different responses to treatments, different histologies 
and different genetic causes. In 2009, it was reported that 5% of kidney cancers occurred in 
the ureter, 7% in the renal pelvis, and 86% in the rest of the kidney (Cancer Research UK)(see 
fig 3). Kidney cancers are classified based on molecular genetics findings together with 
cytomorphological features, into a minimum of five main histological subtypes: medullary-
collecting duct carcinoma (1%), chromophobe (5%), oncocytoma (5%) papillary (10%), and 
clear cell (75–80%),(see Fig 4) (Linehan et al. 2004, Kovacs et al. 1997, Murakami 2007). 
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 (VHL= Von-Hipple-Lindau; FH= Fumarate Hydratase ) 
Fig 4: Stained tissue sections showing differences in morphology between tumour types (Linehan 
et al., 2004) 
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The identification of rare familial cancer genes has provided important insights into the 
pathogenesis of both familial and sporadic cancers. In this way the identification and isolation 
of the susceptibility genes for von Hipel-Lindau (VHL) disease allowed it to be shown that 
somatic inactivation of the VHL tumour suppressor genes (TSG) play a critical role in the 
development of the majority of sporadic clear cell and renal cell carcinoma (Latif et al. 1993, 
Foster et al. 1994, Gnarra et al. 1994). The identification of the VHL tumour suppressor 
genes’ products and the clarification of its function, as well as the role of the von Hippel 
Lindau tumour suppressor protein (pVHL) in regulating hypoxia-inducible transcription 
factors, HIF-1 and HIF-2, by facilitating the oxygen-regulated break down of HIF-alpha, 
brought about the introduction of tyrosine kinase inhibitors, such as the drugs sunitinib and 
sorafenib discussed above, for the treatment of advanced sporadic RCC and clinical trials of 
these agents in VHL disease management (Maxwell et al. 1999, Feldman and Motzer 2006). 
Investigation of the function of rare genetic disorders may allow development of treatments to 
improve the management of diseases in both patients with the comparatively more common 
non-familial disorders as well as the familial diseases including Birt-Hogg-Dubè Syndrome. 
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Birt-Hogg-Dubé Syndrome 
 
Fig 5: Non-renal manifestations of BHD: Multiple fibrofolliculomas. (Cartwright et al., 2008) 
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Fig 6: Non-renal manifestations of BHD: multiple pulmonary cysts. (Cartwright et al., 2008) 
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Fig 7: A shows the multiple white to skin-coloured, dome-shaped, smooth papules on the face of 
a BHD patient; B shows the family pedigree of an Asian family with a BHD germ-line mutation; 
C shows the histopathology of one of the papules in the 67-year-old proband, a Japanese woman, 
showing the features of fibrofolliculoma. (Noriyuki Misago et al., 2008) 
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Birt-Hogg-Dubé (BHD) syndrome is a multisystem, autosomal dominantly inherited disorder 
characterised by the development of benign skin tumours on the face and upper body in the 
third decade of life (Birt et al. 1977). Histological examination of the tumours reveals them as 
fibrofolliculomas or trichodiscomas (Fig 5 &7) Fibrofolliculomas are highly penetrant. 85% 
of patients diagnosed with BHD mutations develop these classical dermatological symptoms 
which can be a cosmetic problem and cause concern to some patients. Statistics regarding 
individuals with fibrofolliculoma without identified FLCN mutations are unavailable. BHD 
occurs in about 1/200,000 people (Cartwright et al., 2008), although it may be under-reported 
due to lack of recognition. BHD is caused by mutations in the folliculin (FLCN) gene which 
is located on the short arm of chromosome 17 (17 p11.2). Additional features of BHD include 
susceptibility to pulmonary cysts and pneumothorax (Fig 6). Pulmonary cysts develop in over 
80% of BHD patients, and almost 25% suffer pneumothorax (Zbar et al., 2002, Toro et al. 
2007, Toro et al. 1999, Linehan et al. 2003). The condition also carries an increased risk of 
kidney cancer and there have been some reports of colorectal polyps and colorectal cancer 
being observed in association with BHD syndrome (Rongioletti et al., 1989, Zbar et al., 
2002). Genetic testing identifies FLCN gene mutation in 84 % of clinically diagnosed BHD 
cases. Renal tumours occur in 25-35% of BHD patients (Zbar et al., 2002, Toro et al.1999, 
Pavlovich et al. 2002) and they are often bilateral and multifocal. Histology is often an 
oncocytic hybrid (50%).The multifocal hybrid chromophobe-oncocytoma renal carcinoma 
histological subtype is only seen in BHD patients with chromophobe RCC and oncocytoma 
features and a combination of individual tumour cell populations within a hybrid tumour 
(Yang et al. 2008). Chromophobe renal cancer histological subtype is also often seen (33%), 
but tumours could also be of a clear cell renal cancer type (9%), or benign oncocytomas (4%) 
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(Pavlovich et al., 2002) (% of BHD patients affected is shown in table 1). This is quite a 
different distribution to the general distribution discussed before. 
Table 1: Estimaed percentage of BHD patients affected by cancers. 
Tumor type % of BHD patients affected (approximation ) 
oncocytic hybrid 12 
Chromophobe 8  
clear cell RCC 2 
Oncocytoma benign 1 
 Calculated given a 25% cancer incidence rate 
in BHD patients (see above) 
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Fig 8: A Chromophobe renal carcinoma (top), hybrid-oncocytic neoplasms showing features of 
both tumor types with stained and non stained areas (centre) and oncocytoma (bottom). Taken 
from ×20 (top and centre) and ×40 (bottom). From Birt Hogg Dubé-associated bilateral, 
multifocal renal tumours (Linehan et al. 2004) 
19 
 
 
 
 
Fig 9: Birt Hogg Dubé-associated bilateral, multifocal renal tumours: (Linehan et al., 2004) 
Fig 8 and fig 9 show multiple independent tumours of different sorts with different 
morphologies and properties that developed following one initial mutation. This may occur in 
one or often both of the patients’ kidneys. 
Investigation of a mutation hotspot in genotype/phenotype analysis by Schmidt et al. (2005) 
and Toro et al. (1999) showed germ-line deletion of cytosine at exon 11 in the FLCN gene 
appears as though it may lead to fewer renal tumours in BHD patients than insertion of 
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cytosine at the same point (c.1733insC, c.1733delC, see fig 10). How, when and where the 
mutation occurs could all affect the outcome for the individuals affected although no 
genotype-phenotype correlations have been confirmed to date. 
The first reported renal cancer in a BHD patient was in 1993 by Roth et al. The occurrence of 
multiple renal tumours in a BHD patient was reported by Toro et al. (1999) and Roth et al. 
(1993). Statistical association of renal tumours and pulmonary problems with BHD was 
published in 2002 by Zbar et al..  
The BHD gene FLCN encodes a 64 kDa protein, known as folliculin (Nickerson et al., 2002). 
In kidney tumours, the wild-type allele of FLCN has been seen to have undergone somatic 
mutation and deletion or loss of heterozygosity, which supports the widely held idea that 
FLCN follows the Knudson 2-hit hypothesis and is in fact a classic tumour suppressor gene. 
No homology to other known proteins could be found for the FLCN protein and it has no 
predicted functional domains identifiable. FLCN is a highly conserved protein across many 
species which gives an indication that it could possibly have an essential role in development. 
This is supported by the observation that absence of all FLCN in mice leads to embryonic 
lethality from visceral endoderm defects (Baba et al., 2012). 
Molecular Biology 
Although the protein sequence of folliculin did not contain any obvious functional motifs to 
indicate a likely function, reports have linked folliculin function to the mTOR pathway, the 
mammalian target of rapamycin kinase (Baba et al., 2006). Disregulation of the mTOR 
pathway is common in sporadic RCC and one promising therapy for advanced RCC is the 
mTOR inhibitor, temsirolimus, (Robb et al., 2007, Hudes et al., 2007).  As can be seen in 
Fig10, nearly all BHD mutations are frame shift or nonsense mutations that are predicted to 
prematurely truncate the BHD protein FLCN. Mutation of FLCN in sporadic kidney cancer is 
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not common but has been seen (Da Silva et al., 2003, Murakami et al. 2007), although the 
exact frequency of such FLCN mutations is unknown. Mutation analysis was performed in 35 
CRCs and cell lines, and 30 RCC primary tumours and cell lines. A somatic missense 
mutation with loss of the wild type allele was identified in a primary clear cell RCC (showing 
consistency with the two hit tumourigenesis mechanism), and a further missense mutation 
was detected in a clear cell RCC cell line. A somatic missense substitution was detected in a 
primary CRC, as well as three oncocytoma type RCCs for which matched normal DNAs were 
not available. A germline missense variant was found in a primary CRC and not detected in 
40 control individuals or a further 159 familial and sporadic CRC cases. No evidence of 
epigenetic silencing of BHD in was found. Da Silva et al (2003) concluded that the findings 
suggested that BHD inactivation occurred in a subset of clear cell RCC and CRC. Shin et al 
(2003) also reported BHD frameshift mutations in a subset (∼20%) of MSI+ CRCs with 
micro satellite instability. The most recent data gives the rate of FLCN mutation in sporadic 
clear cell RCC as 0.2% (1in 418 cases) and 2.8% of 72 cases for CRC (www.cbioportal.org 
02/05/2014) 
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Fig 10: Diagram showing the positions and nature of documented mutations that have been 
found within the BHD gene (taken from Toro et al., 2008). 
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In the case of FLCN, mutations occurring 5’ in the gene, rendering large parts of the protein 
absent, might have greater effects than mutations in the 3’ coding regions and /or those that 
affect just a small section of the protein, unless they affect a necessary structural or functional 
component of the protein produced. 
A human FLCN-binding protein (Fnip1) was identified in 2006(Baba et al., 2006). It is 
evolutionally conserved, and also interacts with the AMPK complex. Both FLCN and Fnip1 
are phosphorylated by AMPK and the phosphorylation of FLCN is regulated directly or 
indirectly by Mammalian Target of Rapamycin (mTOR). The phosphorylation of S6K1 may 
also be affected by expression of FLCN (Baba et al., 2006). The interactions with the AMPK 
and mTOR pathways indicate probable involvement in energy/nutrient sensing. A second 
FLCN-binding protein, called Fnip2 or FnipL (for Fnip1-Like), which is highly homologous 
to Fnip1, was reported by two groups (Hasumi et al., 2008, Takagi et al. 2008). Fnip2 could 
positively regulate phosphorylation of FLCN. It binds to phosphorylated FLCN. A role of 
Fnip2 may be to stop dephosphorylation of FLCN by the formation of a FLCN/Fnip2 
complex. Fnip2 is bound and phosphorylated by AMPK. The parts that these 
phosphorylations, and that of FLCN by AMPK (Baba et al., 2006), play in the functions of 
Fnip1, Fnip2 and FLCN are not yet known. FNIP1 knockdown exerted a similar effect as 
BHD; the FLCN-FnipL and Flcn-Fnip1, complexes may function independently in the mTOR 
pathway. Suppression of FLCN, their common factor, may give greater effects than 
suppression of Fnip (Takagi et al. 2008, Hasumi et al., 2008). Hasumi et al. also found a 
binding between Fnip1 and Fnip2.  
mTOR-pathway  
Mammalian Target of Rapamycin (mTOR), a member of the PIKK (Phosphatidylinositol 3-
Kinase-related Kinase) family is a serine/threonine protein kinase of 289-kDa in size. The 
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mTOR pathway is regulated by many cellular signals, including nutrients (amino acids, 
glucose), mitogenic growth factors, cellular energy levels, hormones such as Insulin, and 
stress conditions. The PI3K/Akt pathway, involved in the mediation of cell survival and 
proliferation, acts through mTOR.  
 
Fig 11: The mammalian target of rapamycin mTOR signalling pathways (Linehan et al., 2010). 
Fig 11 shows the basis of FLCN interaction through the mTOR pathway. FLCN loss may lead 
to disease through actions of mTOR and AMPK signaling. 
FLCN, VHL and other genes that have been shown to cause kidney cancer have a feature in 
common, in that they are all involved in iron, energy, oxygen, or nutrient sensing pathways, 
indicating that kidney cancer is a metabolic disease. AMPK, the cells’ primary energy sensor, 
is bound by the FLCN–FNIP1–FNIP2 complex and a kinase that is rapamycin-sensitive (e.g. 
mTORC1) phosphorylates FLCN.  The LKB1–AMPK cascade phosphorylates TSC1–TSC2 
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thus helping mediate the response of the cell to energy and nutrient sensing. (Linehan et al., 
2010)  
Animal models 
Animal models of human cancer are valuable tools for identifying pathways responsible for 
neoplasia and drug testing prior to any clinical trials. A targeted BHD- kidney-specific mouse 
model which has a marked polycystic phenotype which develops within the first 3 weeks of 
life has been developed. In this model, homozygous inactivation of BHD leads to cell 
proliferation, although BHD-null cells may still require additional genetic or epigenetic events 
to gain a growth advantage and to facilitate progression to cancer. These BHD-targeted mice 
develop a recognisable kidney phenotype over a very short time. For this reason this model 
may be useful for the testing and development of drugs and therapies, even though the mouse 
model may not precisely mirror BHD syndrome (Baba et al. 2008). 
The mouse model also indicated that BHD is needed for the proper regulation of cell growth 
(Baba et al. 2008) and proliferation through Akt-mTOR signalling (Fig 11, vida supra) during 
postnatal kidney development (Baba et al. 2008). The resulting inappropriate Akt-mTOR 
signaling could play a part in the observed phenotype of enlarged cystic Kidneys. This is 
reinforced by the reduced kidney size and tubule/duct dilatation seen with rapamycin 
treatment, which extended survival of BHD knockout mice (Baba et al., 2008).  
Flcn mutant Nihon rats are a model of renal cell carcinoma (RCC). They originated from a 
Sprague-Dawley strain of rats. A germline mutation in the rat homologue of the BHD gene 
was identified (Okimoto et al., 2004b) in these rats, a single nucleotide insertion on 
chromosome 10, within exon 3 of Flcn (c.462_463insC). The mutation results in a frameshift 
and premature stop codon within the Flcn gene (Okimoto et al., 2004b).  Heterozygous Nihon 
rats develop RCCs that mainly show clear-cell histology. Homozygous mutants are 
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embryonic lethal (Okimoto et al., 2004a). Suppression of the Nihon rat phenotype by 
introduction of a wild-type BHD mini-gene was then shown (Togashi et al., 2006) allowing 
the Nihon rat to be used as an animal model of BHD.  
The German Shepherd dog-model consists of a hereditary multifocal renal 
cystadenocarcinoma and nodular dermatofibrosis (RCND) associated with a adenine to 
guanine missense mutation was detected in exon 7 of the canine BHD gene on canine 
chromosome 5. This nucleotide change gives rise to a histidine-to-arginine mutation in the 
protein expressed (Lingaas et al., 2003). 
It is the intention of the project to investigate the role of FLCN in the cell and in the 
development and treatment of BHD syndrome, using a variety of techniques including tissue 
culture, molecular biology and genetics. 
Aims 
The study will make use of molecular techniques such as cell culture and Western blotting, as 
well as antibody staining and microscopy (including confocal microscopy). These methods 
will be employed to study the molecular pathology of BHD. 
Treatment of BHD-related tumours (and sporadic tumours with FLCN inactivation) could 
possibly be targeted by developing treatments that target cells without FLCN protein 
specifically. There are several ways in which possible therapeutic agents could be selected 
according to a number of criteria. Agents that target signalling pathways linked to FLCN 
function could be investigated. An approach based in bioinformatics, as described for VHL 
(Sutphin et al., 2007) could be employed to pick out chemical treatments that are likely to 
show selective toxicity against FLCN negative cells. To this end the NCI-60 cell lines 
collection (representing renal, colon, lung, melanoma, leukaemia, central nervous system, 
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prostate, breast and ovarian tissues), which have been tested for sensitivity to greater than 
60,000 chemical compounds, could be ranked using expression levels of the FLCN gene in 
each cell line and correlated with sensitivity to each specific compound so as to allow 
identification of compounds that could potentially be differentially cytotoxic according to 
FCLN expression levels. 
Potential FLCN-negative specific agents can then be tested against a panel of cells including 
UOK257 (Youfeng Yang et al. 2008) and cells transfected with wild-type and mutant FLCN 
constructs. Investigation into the effect of chemicals that affect folliculin-associated signalling 
pathways could be carried out beginning with in vitro tumourigenesis assays (e.g. colony 
formation assays) to pick out chemicals  with different results depending on FLCN status, and 
testing cytotoxic compounds in clonogenic survival assays (Sutphin et al,. 2007). The effect 
of chemicals on caspase activity of cells with different FLCN levels and mutations will also 
be of interest, as will other genes that may affect the survival in FLCN-deficient cells. 
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Chapter 2: Materials and methods 
Cell Lines and Cell Culture. 
Human renal carcinoma of BHD origin cells UOK-257 (UOK-FLCN
-
) and FLCN transfected 
UOK-257 cells UOK-FLCN
+
 (Yang et al., 2008) were provided by Dr Marston Linehan and 
Dr. Laura S Schmidt (Urologic Oncology Branch, Centre for Cancer Research, National 
Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA) to whom we are 
grateful. FTC-133 cells were purchased from the European Collection of Cell Cultures 
(ECACC) (Salisbury, United Kingdom). Transfection of FLCN constructs into FTC cells and 
selection of stable clones was carried out by Laurence Seabra. Other RCC cell lines, including 
786-0, SKRC47, CAKI2 and stable transfectants of 786-0, SKRC39 and RCC4. containing a 
construct (VHL+, or empty vector for control), were obtained from Dean Gentle. All cell lines 
were cultured in Dulbecco's Modified Eagle Medium (DMEM) with supplement of 10% 
foetal bovine serum except for FTC-133 cells which were incubated in medium containing 
DMEM and Ham’s F12 nutrient mixture (1:1). 
Cells were incubated at a temperature of 37 ºC with high humidity levels and elevated CO2 
concentrations (usually 5% ) to maintain the proper pH (7.4 ± 0.2) used with bicarbonate 
buffer medium, and using unsealed dishes and plates or flasks with gas permeable (vented) 
caps to allow gas exchange. Cell culture media used are shown in Table 2 and Table 3. 
Table 2: Media used in cell cultures 
DMEM 500 ml Final conc 
Foetal Bovine Serum 50 ml 10% 
200mg/ml Glutamine 5 ml 2 mg/ml 
 (All purchased from Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, 
Gillingham, Dorset SP8 4XT) 
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Table 3: Cell culture media for FTC-133. (FTC-133 cells were purchased from ECACC 
(Salisbury, United Kingdom). 
  Final conc. 
DMEM  250ml  
Ham’s F12  250ml   
Foetal Bovine Serum  50ml  10% 
200mg/ml Glutamine  5ml  2 mg/ml 
For stably-transfected clones, G-418-Sulphate-solution (P11-012 from PAA Laboratories Ltd, 
Termare Close, Houndstone Business Park, Yeovil, Somerset, BA22 8YG, United Kingdom) 
was added to give selection pressure to keep only the transgenic cells. 1 ml of the G418 
solution was added per 100 ml of medium. 
Stable expression of an artificially introduced DNA sequence is achieved by integration of the 
gene of interest into the target cell's chromosome, along with an antibiotic resistance gene to 
allow the cells containing the construct to be selected and non-transfected cells to be removed 
so that they do not affect the results of the experiments or overgrow the transfected cells.  
Frozen cell vials were taken from the liquid nitrogen tank, the dry ice on which they were 
shipped, or a -70 °C freezer and the vials were then left at room temperature for 2 minutes. 
The frozen cells were then melted by immersing the vials in a 37 °C water bath. Working in a 
class 2 hood, 5ml of medium plus the melted cells (~1 ml) were pipetted into the labelled 
Universal tubes. Centrifuge down cell pellet at 1000 rpm for 3 minutes. The cell pellet was 
then re-suspended in 5ml medium and incubated at 37 °C. 
Flasks of actively growing cells were prepared, and used at 80 to 90% confluence. 1x Trypsin 
solution (purchased from Sigma) was used to dissociate cells prior to seeding. 
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Small interfering Ribonucleic acid (SiRNA) treatment for reverse transfection with 
INTERFERin®.  
A double-stranded RNA molecule is cleaved to give single-stranded RNA (usually from 21 to 
25 nucleotides in length) which then binds to complementary sequences in messenger RNA 
(mRNA) and brings about the cleavage and degradation of the mRNA thus preventing the 
production of the protein coded by that molecule. 
Work was carried out in the Tissue Culture sterile lamina flow hood. Reagents were warmed 
to room temperature. Appropriate volumes of Opti-MEM® Reduced Serum Medium (11058-
021 no Phenol Red, from Invitrogen Life Technologies Ltd,3 Fountain Drive, Inchinnan 
Business Park, Paisley, PA4 9RF, UK) and SiRNA for each required treatment were added to 
separate wells of a 96-well plate. These were mixed well using the plate shaker. This diluted 
siRNA (folliculin siRNA(h), Santa Cruz Biotechnology 2145 Delaware Avenue Santa Cruz, 
USA) and SSH2 siRNA (Silencer Select human Phosphatase siRNA Library, Ambion, 
Warrington, UK) transfection reagent (INTERFERin, Polyplus Transfection, Hampshire, UK) 
was then added to each of these wells and the plate well mixed for 10 minutes on the plate 
shaker. These SiRNA treatment mixes were aliquoted into the appropriate wells of the 
experimental plates at a final volume of 10 μl per well in a 96-well plate with exponentially 
growing cells for growth inhibition assays (or scaled up for 12 well plates, 6 well plates, or 10 
cm dishes for confocal analysis or clonogenic assays). The final siRNA concentration was at 
20 nM. After being siRNA transfected, the plates were then mixed gently and incubated at 37 
°C for 24 hours. Drug treatments were then added and the plates were incubated for a further 
72 hours, after which the cells were fixed and stained. The cells were trypsinised and the cells 
counted and seeded at 90 μl of cell suspension per well of 96-well plates at a low density. The 
exact density depended on the cell line used and is shown in Table 4. 
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Table 4: Experimental cell seeding densities 
Cell line Concentration of cells and Size 
of well 
 
INFO 
UOK257
 
3-5 x 10
4
 cells / ml (3-5 x 10
3 
cells/ 100 µl/well) 
 HUMAN CLEAR CELL RCC FROM A MALE BHD PATIENT'S KIDNEY TISSUE 
C.153C>T MUTATION RESULTED IN AN EARLY TRUNCATION OF P53 PROTEIN 
(WILD TYPE PTEN  PRESENT ) 
FLCN FRAMESHIFT MUTATION [C.1285DUPC; PREDICTED, IN THE ABSENCE OF 
NONSENSE MEDIATED MRNA DECAY, TO LEAD TO PREMATURE PROTEIN 
TRUNCATION (P.HIS429PROFSX27) ( lu et al 2011) 
FTC-133 2.5 x 10
4
 cells / ml (2.5 x 10
3
 
cells/ 100 µl/well) 
 SOMATIC FLCN GENE MUTATION (C.1285DELC) 
PTEN GENE MUTATION RESULTING IN A TRUNCATED PROTEIN 
 POINT MUTATION OF P53 GENE LEADED TO INACTIVATION OF P53 FUNCTION  
BY ACCUMULATION OF THE PROTEIN. .(lu et al.2011) 
CAKI 2 5 x 10
4
 cells / ml (5 x 10
3
 cells/ 
100 µl/well) 
 LOSS-OF-FUNCTION SUBSTITUTION - NONSENSE MUTATION IN THE VON 
 HIPPEL-LINDAU (VHL) TUMOR-SUPPRESSOR PROTEIN C.529A>T P.R177* 
PTEN WILD TYPE 
CAKI1 6 x 10
4 
cells / ml 
  VHLWILDTYPE(http://www.medogene.com/My%20Researches/Kidney%20cell%20lines.html) 
 P53 WILD TYPE AND PTEN  WILD TYPE 
SKRC45 2 x 10
4 
cells / ml 
 VHL MUTATION R82P (Gemmil et al. 2005) 
SKRC47 2 x 10
4 
cells / ml 
 VHL MUTATION 
SKRC39 10
4 
cells / ml 
  VHL MUTATION Jafri et al, 2012FLCN ALA238VAL (C.1168 C→T) SUBSTITUTION, 
PATHOGENICITY UNCONFIRMED(da Silva et al.2003) 
 
786-0 10
4 
cells / ml 
 -/-NON-FUNCTIONAL VHL (1 BASE DELETION)(Wada et al. 1999) 
 P53 MUTATION C.832C>GPROTINE CHANGE C.560-2A>G  (SPLICE JUNCTION) 
EFECT INCONCLUSIVE, 
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Sulforhodamine B (SRB) Growth Inhibition Assay 
The Sulforhodamine B assay (SRB) (Skennan et al., 1990) was used to assess the sensitivity 
of the cell lines to growth inhibition caused by chemical treatment. Exponentially growing 
adherent cells were seeded into 96-well plates wells B2 – H11 (10 x 6) at a suitable density –
see Table 4. 
Allowing for 24 hrs settling down and 72 hours growth, 100 µl medium was put into the 
outside wells to compensate for ‘edge effect’. In another plate 5-wells of cell suspension were 
seeded in one row for each cell line and these were surrounded by media containing wells to 
avoid edge effect. This was the Day 0 plate. After 20-24 h incubation at 37 °C, the day 0 plate 
was fixed by adding an equal volume of Carnoy’s fixative and stored at 4 °C until staining. 
Also after 20-24 h incubation, drugs were added to the experimental wells at the appropriate 
concentrations for each compound tested. One row (five replicates) was treated for each drug 
concentration. 10x drug final concentrations in 10% dimethyl sulfoxide (DMSO) were 
prepared (DMSO plus five concentrations were used for each experiment by adding 12.3 μl 
100x into 100 μl medium in a 96-well format) see table 5. 
10 μl of this 10x solution was then added into the appropriate wells containing 100 µl medium 
to give the final 1x concentration and 1% DMSO. The drug was mixed with the medium in 
the wells by placing the plate in a plate shaker for 2 minutes. The plates were then incubated 
at 37
o
C for 72 hours.  
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Table 5: Drug concentrations 
Compound 
1x Solution 
Concentration 10x Solution Concentration 
 Morpholino-ADR 0.01, 0.1, 1, 10, 100 nM 0.1, 1, 10, 100, 1000 nM 
 Cyanomophorlino-ADR 0.01, 0.1, 1, 10, 100 nM 0.1, 1, 10, 100, 1000 nM 
Echinomycin 0.01, 0.1, 1, 10, 100 nM 0.1, 1, 10, 100, 1000 nM 
      
Chromomycin A3 0.1, 1, 10, 100, 1000 nM 0.001, 0.01, 0.1, 1, 10 µM 
Bruceantin 0.1, 1, 10, 100, 1000 nM 0.001, 0.01, 0.1, 1, 10 µM 
Vincristine sulphate 0.1, 1, 10, 100, 1000 nM 0.001, 0.01, 0.1, 1, 10 µM 
DidemninB 0.1, 1, 10, 100, 1000 nM 0.001, 0.01, 0.1, 1, 10 µM 
      
Taxol 0.001, 0.01, 0.1, 1, 10 µM 0.01, 0.1, 1, 10, 100 µM 
Mithramycin 0.001, 0.01, 0.1, 1, 10 µM 0.01, 0.1, 1, 10, 100 µM 
 Phyllanthoside 0.001, 0.01, 0.1, 1, 10 µM 0.01, 0.1, 1, 10, 100 µM 
      
Bisantrene hydrochloride 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
Doxorubicin 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
Rapamycin 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
VM-26 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
Menogaril 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
N,N-dibenzyldaunomycin 0.01, 0.1, 1, 10, 100 µM 0.1, 1, 10, 100, 1000 µM 
 
After drug treatment for 72 hours, the cells were fixed in situ by adding an equal volume of 
Carnoy’s fixative (methanol: acetic acid=3:1) to each well containing cells.  This was then 
placed at 4
o
C for at least 1 hour and up to one week before SRB staining. The plates were 
then washed in water and air dried. 100 µl of SRB solution (0.4 % w/v Sulforhodamine B 
Solution dissolved in 1% w/v acetic acid (Sigma-Aldrich, Poole, United Kingdom)) was 
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added to each well and left for 30 minutes at room temperature, after which time the plates 
washed with 1% w/v acetic acid solution to remove all excess stain. The acetic acid solution 
was then removed and the plates placed in the drying oven until dry. Prior to reading the 
plates, the protein-bound SRB was solubilised by the addition 10 mM Tris Base (pH 10.5) to 
each well. Gentle agitation in a plate mixer was used to ensure a completely homogenous 
solution. 
The absorbance for each well was measured at 570 nm on a Victor X3 Multilabel Plate 
Reader (PerkinElmer, Beaconsfield, United Kingdom). 
Carnoy’s fixative: methanol: acetic acid=3:1, store at 4 oC. 
 (Morpholino-ADR (NSC 354646), Cyanomophorlino-ADR (NSC 357704), Echinomycin 
(NSC 13502), Chromomycin A3 (NSC 58514), Bruceantin (NSC 67574), Vincristine sulfate 
(NSC 165563), DidemninB B (NSC 325319), Paclitaxel (Taxol, NSC 125973), Mithramycin 
(NSC 24559), Phyllanthoside (NSC 266492), Bisantrene hydrochloride (NSC 337766), 
doxorubicin (Adriamycin, NSC 123127), VM-26 (Teniposide, NSC 122819), Menogaril 
(NSC 269148), N,N-dibenzyldaunomycin (NSC 268242), and rapamycin (NSC 226080) were 
kindly provided by the Developmental Therapeutics Program of the National Cancer Institute 
(NCI)/NIH (http://dtp.nci.nih.gov). ) Compound C AMPK Inhibitor, 6-[4-(2-Piperidin-1-yl-
ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin (171260  -1MG) 
was obtained from Calbiochem MERCK. 
The levels of growth inhibition induced by the various concentrations of agents were 
measured in all cases, after 72 hours of treatment. GI50 values were calculated by fitting a 
sigmoidal concentration/inhibition curve to the data obtained from the SRB assays, using non-
linear least square regression (Graph Pad PRISM
TM
). 
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Clonogenic Cell Survival Assay 
The ability of Mithramycin to kill cells and the efficiency with which it did it was investigated 
in UOK-257 cells with (UOK FLCN) and without (UOK257) FLCN expression.  
Exponentially growing cells were seeded into 10 cm tissue culture plates at several densities 
from 250 to 1 x 105 cells per dish. Two seeding densities in duplicate for each seeding density 
were set for the experiment. The cell seeding density was calculated to give an estimated 10-
300 colonies/plate following drug exposure. DMSO controls and five concentrations of 
Mithramycin treatment were used for each cell line (see tables 6 and 7) 
Table 6: Mithramycin concentrations and cell numbers used in clonogenic assay with the UOK 
cell line. 
UOK:       
Mithramycin concentration / nM 0 10 50 100 200 500 
Seeding density/plate  150 150 500 1000 5000 5000 
 300 300 1000 5000 10000 10000 
 
Table 7: Mithramycin concentrations and cell numbers used in clonogenic assays with the UOK-
FLCN cell line. 
UOK-FLCN:       
Mithramycin concentration / nM 0 100 200 500 1000 10000 
Seeding density/plate  150 150 150 500 1000 5000 
 300 300 300 1000 5000 10000 
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The cells were trypsinised and counted following standard procedures and the cells diluted to 
the appropriate seeding density in the medium. The maximum volume used in each 10cm 
plate is 10ml. All plates were then incubated for 24 h at 37
o
C to allow the cells to attach.  
Solution was made up and 70µl of 100x Mithramycin (dissolved in DMSO) was added to give 
the final concentrations given above in the dishes. The final concentration of DMSO in the 
medium was 1%. At least three experiments were carried out under each set of conditions. All 
plates were incubated for 72hrs. 
At the end of this time the drug-containing medium was removed from all cells and they were 
washed gently once with 5ml of warm PBS. 10ml fresh medium was added into each of the 
plates and all plates were incubated for an additional 10 to 15 days. The medium was then 
carefully removed and the cells were fixed in situ by adding Carnoy’s fixative mixed with an 
equal volume of PBS to each plate containing cells; this was then removed after a short 
incubation at ambient temperature and the plates placed at 4
o
C for at least 1 hour and up to 
one week and air-dried before SRB staining. SRB solution (Sigma-Aldrich, Poole, United 
Kingdom) was added to each of the plates and left for 30 minutes at room temperature. After 
this time the plates were washed with 1% w/v acetic acid solution to remove all excess stain. 
The acetic acid solution was then removed and the plates dried in the drying oven. Colonies 
with over 30 cells were counted. Cloning efficiencies of untreated cells were: UOK257-
FLCN
-
 26% and UOK257-FLCN
+
 34%. Cell survival following drug exposure was expressed 
as % control cloning efficiency or survival. 
SSH2 Clonogenic Cell Survival Assay 
The ability of SSH2 siRNA knock-down to kill cells and the efficiency with which it did it 
was investigated in FTC133 cells with (FTC133-12) and without (FTC133-22) FLCN 
expression.  
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Exponentially growing cells were seeded into 10 cm tissue culture plates at several densities 
from 100 to 4000 cells per dish. Two sets in duplicate for each treatment concentration were 
set for the experiment. The cell-seeding density was calculated to give an estimated 10-300 
colonies/plate following treatment exposure. Luciferase controls and four concentrations 
SSH2 siRNA treatment were used for each cell line. 
Table 8: SSH2-siRNA treatment conditiond used for each cell line 
FTC12:     
SSH2 siRNA concentration / nM 1 5 10 20 
Seeding densit cells/plate 900 1200 2000 4000 
luci siRNA concentration / nM 1 5 10 20 
Seeding density/plate  100 100 100 100 
FTC22     
SSH2 siRNA concentration / nM 1 5 10 20 
Seeding density/plate 300 300 500 500 
luci siRNA concentration / nM 1 5 10 20 
Seeding density/plate  600 600 600 600 
 
The cells were trypsinised and counted following standard procedures and the cells diluted to 
the appropriate seeding density in the medium. The maximum volume used in each 10 cm 
plate is 10 ml. All plates were then incubated for 24 h at 37°C to allow the cells to attach. 
SiRNA knock-downs were carried out as described above with the amounts scaled up for the 
larger plates. All plates were incubated for 72 hours. 
Once again at the end of this incubation time the drug-containing medium was removed from 
all cells and they were washed gently once with 5 ml of warm PBS. 10 ml fresh medium was 
added into each of the plates and all plates were incubated for an additional 10 to 15 days. The 
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medium was then carefully removed and the cells were fixed in situ by adding Carnoy’s 
fixative mixed with an equal volume of PBS to each plate containing cells. This was then 
removed after a short incubation at ambient temperature and the plates placed at 4
o
C for at 
least 1 hour and up to one week and air dried before SRB staining. SRB solution (Sigma-
Aldrich, Poole, United Kingdom) was added to each of the plates and left for 30 minutes at 
room temperature, after which time the plates were washed with 1% w/v acetic acid solution 
to remove all excess stain. The acetic acid solution was then removed and the plates dried in 
the drying oven). Colonies with over 30 cells were counted. Cloning efficiencies of untreated 
cells were: UOK257-FLCN
-
 26% and UOK257-FLCN
+
 34%. Cell survival following drug 
exposure was expressed as % control cloning efficiency or survival. 
Western Blot Analysis  
Cellular protein expression in cells with/without FLCN protein were identified from complete 
cell lysate obtained after 48 h treatment and the changes due to the treatments applied to the 
cells determined.  
Cells were cultured in plates until they reached 80% confluence. They were then washed with 
5ml PBS which was aspirated. 5ml PBS was added into each plate and cells detached by a cell 
scraper (rubber policeman). The cell-containing PBS was transferred into a universal tube and 
centrifuged down at 1000rpm for 3minutes to give a cell pellet. The supernatant was removed 
and the pellet re-suspended in 1ml PBS, which was then transferred into an Eppendorf tube 
and centrifuged down to give a cell pellet at 2000rpm for 1 minute. The supernatant was 
removed and all tubes stored at -70
o
C. Lysis buffer (6.25mM Tris HCl pH6.8, 10% glycerol, 
2%SDS) was then added to the pellet to disrupt the cells. 
DC protein assay kit was used to test the protein concentrations in the lysate samples. The 
manufacturer’s instructions were followed (Bio-Rad Laboratories Ltd, Hertfordshire, United 
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Kingdom). Electrophoresis was carried out on 20 µg samples of protein on 12.5% (w/v) SDS-
PAGE gels (using BIORAD Mini-PROTEAN® Tetra electrophoresis system, following 
manufacturer’s instructions, at 100v for approximately 1 hour) and then electro-blotted (using 
BIORAD Mini Trans-Blot® Cell system, following manufacturer’s instructions, at 100v for 1 
hour) on to nitrocellulose membrane (Amersham Pharmacia Biotech UK Ltd., 
Buckinghamshire, United Kingdom). The membrane was then washed in PBStw (PBS with 
0.1% tween 20 added, both obtained from Sigma-Aldrich Company Ltd) in which milk 
protein had been dissolved at 5% to block non-specific binding. Primary antibodies were then 
used to probe for the proteins of interest. The antibodies diluted 1:100 to 1:1000 in 5% milk 
PBStw were applied to the membrane and incubated overnight at 4
o
C. After the removal of 
the primary antibody the membrane was washed in PBStw, a secondary antibody appropriate 
to the primary antibody (anti-mouse IgG-HRP conjugate, or an anti-rabbit IgG-HRP 
conjugate (DAKO, Ely, United Kingdom)) was used at a concentration of 1:2000 in 5% milk 
PBStw incubated at room temp for 2 hours to bind the primary antibody. The bound HRP 
conjugate in conjunction with the enhanced chemiluminescence (ECL+Plus, Amersham) 
system was used to produce a signal which was detected using Kodak film following the 
manufacturers recommended method.  
Antibodies used were against FLCN (generously provided by Prof. Arnim Pause, Rosalind 
and Morris Goodman Cancer Centre Montreal, Canada) and a further FLCN antibody, 
caspase3, pS6 Ribosomal, pAMPKα, p AMPK β, AMPKα and AMPKβ all obtained from 
Cell Signaling Technology, Hertfordshire, United Kingdom. The p53 antibody was DO7, 
Novacastra, Newcastle upon Tyne, United Kingdom and the Actin antibody was obtained 
from Sigma-Aldrich Company Ltd., Dorset, United Kingdom. 
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Immunofluorescence  
Solutions  
PBS  
4% paraformaldehyde: (paraformaldehyde is toxic)  (In a fume hood 4g added to 100 ml of 
PBS which had been warmed to 60
 o
C the bottle was then sealed, and keep warm to dissolve 
when dissolved it was left to cool and aliquots were stored at -20
o
C.) 
0.2% TritonX100 in PBS  
Invitrogen pro long gold mounting medium with Dapi 
Cells were grown on glass cover slips which had been cleaned with ethanol and treated with 
UV light to reduce risk of bacterial contamination. When the cells had grown sufficiently the 
medium was carefully removed and discarded and the cells were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature. The fixative was then removed and 
disposed of appropriately and the cover slips were washed 3 times in PBS. Cover slips were 
then stored in PBS at 4
o
C for up to 5 days. Usually they were used within 24 hours. At this 
point they were permeabilised in 0.2% TritonX100 for 3 to 5 min at room temperature. 
Washed and then blocked for 2 hours in 1% BSA dissolved in PBS. They were then washed 3 
more times in PBS before the cover slip was drained and inverted onto a 50 µl drop of 
primary antibody (diluted 1:100, or 1:1000 for mouse anti-tubulin), on parafilm so that it 
covered all of the cells, throughout the 1 hour incubation. During this time it was kept covered 
and humid. It was incubated for 1 hour at room temp (or overnight at 4
o
C).  
The cover slips were then washed 3 times in PBS. The cover slips were then each inverted 
onto a 50ul drop of secondary antibody (diluted 1:250) on parafilm so that it covered all of the 
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cells, throughout the 1 hour incubation. During this time it was kept in the dark, covered and 
humid. 
A-11005 Alexa Fluor® 594 goat anti-mouse IgG (H+L) *2 mg/ml* 
A-11012 Alexa Fluor® 594 goat anti-rabbit IgG (H+L) *2 mg/ml 
A-11001 Alexa Fluor® 488 goat anti-mouse IgG (H+L) *2 mg/ml 
All from Invitrogen, Life Technologies Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley PA4 
9RF, UK. 
After this they were washed 3 times PBS as before, and then once in dH2O 
The cover slip was then inverted onto drop of mounting medium with Dapi (Invitrogen 
ProLong® Gold ant fade reagent with DAPI P-36931) on labelled slide.  
They were then dried in the dark for 15 min, sealed with clear nail varnish and the slides 
stored at 4
 o
C until they were visualised and photographed using the Leica confocal 
microscope. 
Primary antibodies used were against FLCN (a gift from Prof. Arnim Pause, Rosalind and 
Morris Goodman Cancer Centre Montreal, Canada), FLCN (Cell Signaling Technology, 
Hertfordshire, United Kingdom), Miz (Santa Cruz Biotechnology). (flag) DYKDDDDK Tag, 
Alpha Tubulin and Actin (Sigma-Aldrich Company Ltd., Dorset, United Kingdom) were 
used. Bcl-2, SLK, p15, p21(abcam 330Cambridge Science Park, Cambridge, CB4 0FL UK) c-
Myc (Life Technologies Ltd, 3Fountain Drive, Inchinnan Business Park, Paisley PA4 9RF, UK). 
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Transient Transfection for the expression of over-expression of full-length FLCN or 
FLCN mutants. 
Fugene HD transfection reagent was purchased from Roche (Roche Diagnostics Deutschland 
GmbH, Roche Applied Science, Sandhofer Str. 116, 68305 Mannheim) and used at a 6:2 ratio. 
300µl of opti-MEM (vida supra) was mixed with 6µg of plasmid. 18µl fugene HD was added 
directly to the plasmid medium mixture mixed and incubated for 15 min before being added 
drop-wise to the cells in the 6-well plate. 100µl of transfection mixture per well which 
contains 2 ml of cell suspension. 
The plasmids used were contained flag-tagged full-length normal foliculin, empty vector 
control, two mutant FLCN plasmids Cys82Ala and Cys85Ala, where Cys in FLCN potential 
metal binding domain had been mutated to Ala by site-directed mutagenesis by Uncaar Boora 
who kindly provided the plasmids. 
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Chapter 3: Results of investigations into the effect of FLCN expression on the effect of 
selected drugs 
Selection of compounds with the highest therapeutic potential. 
To determine the most effective drugs to assess, the NCI-60 cell lines database was 
interrogated using the COMPARE algorithm (Developmental Therapeutics Program) by 
Xiaohong Lu and Wenbin Wei, to identify cytotoxic compounds which appeared to be least 
effective against cells with high FLCN protein expression and most effective against cell lines 
with low FLCN protein expression. In principle, this should help identify those drugs which 
may be most use in treating tumours with FLCN inactivation.  
The NCI60 cell line panel was set up from 60 tumour cell lines from nine different tissue 
types as a tissue-directed anticancer drug screen in 1990 by the NCI to evaluate the 
compound’s antineoplastic activity. The 60 cell lines cover a wide range of molecular defects 
so that the analysis of drug activity can be made regarding specific molecular alterations 
(Sutphin et al., 2007). Gene expression for these cell lines was measured using the Gene 
Logic Inc. U95 array and Affymetrix U133 FLCN expression values were extracted. The 
results of this are included in appendix 1. 
The design for the drug sensitivity seed pattern was developed by Xiaohong Lu and Wenbin 
Wei and was similar to protocols previously used for identifying anticancer agents that 
preferentially affect VHL-deficient cell lines by Sutphin et al. (2007). The drug sensitivity 
seed pattern was compared with individual compounds in the DTP database using the 
COMPARE algorithm (Lu et al., 2011).  
To view the correlation of FLCN expression levels to drug sensitivity, FLCN expression of 
the cell lines was determined from publicly available data available through the 
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Developmental Therapeutics Program. This was used to sort the NCI60 cells into three 
groups: those with low FLCN expression, mid FLCN expression, and high FLCN expression. 
A seed pattern, or theoretical drug activity pattern, that would be representative of the target, 
i.e. cells with low or no functional FLCN protein, was built from the FLCN expression 
groupings. The cells known to have high levels of active FLCN were set to have low 
sensitivity to the compound to be selected, and cells known to have very low levels of active 
FLCN or none at all were set to have high sensitivity to the compound to be selected. Mid-
range expressers were of neutral sensitivity. 
A pattern recognition algorithm known as the COMPARE algorithm was used to make a 
comparison of the seed pattern of each of the compounds in the DTP’s Standard Agent 
Database, at the NCI, individually.  The program output was a list of 15 drugs which most 
closely matched the seed pattern of expected sensitivities in the system according to GI50 (the 
concentration of an agent which inhibits cell growth by 50%). The name, structure and 
selected information for these compounds can be seen in Table 9 More detailed information 
about each compound is included in the appendix. Additional compounds selected for their 
known therapeutic activity are also included in Table 9. 
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Table 9: List of compounds selected for further testing by the COMPARE algorithm. 
Compound Name Structure Further info 
(NSC354646) 
Morpholino-ADR 
 
 
(NSC357704) 
cyanomorpholino-
ADR 
 
 
(NSC13502) 
Echinomycin 
 
Binds to DNA and inhibits RNA 
synthesis 
(NSC58514) 
ChromomycinA3 
 
Used as a fluorescent stain of DNA 
and as an antineoplastic agent.   
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(NSC165563) 
Bruceantin 
 
 
 
(NSC67574) 
Vincristine sulfate 
 
Antitumour alkaloid isolated from 
Vinca Rosea. 
(NSC325319) 
Didemnin B 
 
 
 
 
(NSC125973) 
Taxol or paclitaxel 
 
A cyclodecane isolated from the 
bark of the Pacific Yew tree, taxus 
brevifolia. It stabilizes 
microtubules in their polymerized 
form leading to cell death. 
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(NSC24559) 
Mithramycin 
 
Inhibits RNA and protein synthesis 
by adhering to DNA.  
(NSC266492 
Phyllanthoside 
 
 
(NSC337766) 
Bisantrene 
hydrochloride 
 
 
(NSC123127) 
Doxorubicin 
hydrochloride (also 
known as 
adriamycin) 
 
Exerts its antitumour effects by 
interference with the synthesis and 
function of DNA. 
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(NSC 122819 
)VM-26 
Teniposide 
 
Has antitumour activity and forms 
a complex with topoisomerase II 
and DNA and thereby inhibits 
DNA synthesis as this complex 
induces breaks in double stranded 
DNA and prevents repair by 
topoisomthese. Accumulated 
breaks in DNA stop cells from 
beginning the mitotic phase of the 
cell cycle, and lead to cell death. 
Teniposide acts primarily in the G2 
and S phases of the cycle. 
(NSC269148) 
Menogaril 
 
Displays a range of antineoplastic 
activity against a variety of 
tumours. 
(NSC268242), 
N,N-
dibenzyldaunomyci
n 
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Compounds selected separately from the compare algorithm for testing because of their known actions. 
(NSC22608) 
Rapamycin 
 
 
 
 
Selected for its mTOR pathway 
activity. 
Selectively blocks the 
transcriptional activation of 
cytokines thus inhibiting cytokine 
production. It is bioactive only 
when bound to immunophilins.  
Compound C 
 
 
 
Compound c was selected for its 
properties as an AMPK inhibitor 
It has also been shown to promote 
neural differentiation from human 
pluripotent stem cell (hPSC) line 
and to inhibit BMP signals 
necessary for embryogenesis.  
Information on structure and identification of compounds tested obtained from 
http://pubchem.ncbi.nlm.nih.gov/ (19/07/2013) 
 
As a proof of concept that the COMPARE algorithm could effectively select active drugs that 
could differentiate between FLCN+ and FLCN- cells, six of those highlighted as possible 
effective agents and that were easily available were screened. The compounds tested were 
Echinomycin, Chromomycin A3, Vincristine sulfate, DidemninB, doxorubicin and N,N-
dibenzyldaunomycin. 
The initial group of compounds was screened using the SRB growth inhibition assay in 
SKRC47 cells. The SRB assay was chosen as it was known to be a robust method for 
determination of cytotoxicity (Skennan et al., 1990). The SRB stains the fixed cells in the 
plate and excess dye is removed. The dye that is then present in each well is proportional to 
the cells present in each well. The SRB is then re-dissolved and the absorbance measured in a 
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plate reader to establish the amount of dye and there for the amount of cell matter present and, 
from that, the amount of proliferation that has occurred. 
The SKRC47 cell line was chosen as it was an established cell line already characterized and 
in use in the lab for which growth conditions were known. SKRC47 cells are human sporadic 
renal cell carcinoma-derived FLCN positive cells. To give differential FLCN expression, cells 
were treated with FLCN siRNA, to lower FLCN protein expression (giving up to a 90% 
possible reduction according to the data sheet of the transaction reagent). Others were treated 
with luciferase SiRNA as a control. GI50 values for the compounds were calculated in cells. 
In both conditions the GI50 values were compared to allow any FLCN-associated changes in 
sensitivity to these drugs to be identified.  
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Fig 12: Individual dose response curves for the 6 compounds illustrating the dose dependant 
inhibition of growth. 
The estimated concentration of drug required to give a 50% inhibition of growth (GI50) was 
calculated from these graphs plotting the observed inhibitions for the doses given and 
calculating the gradient of the trend line and the value of x (concentration) at which y+50% 
inhibition (values were calculated in Graph Pad PRISM
TM
 by fitting a sigmoidal 
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concentration/inhibition curve to the data obtained from the SRB assays using non-linear least 
square regression). 
Table 10: GI50 for luciferase and FLCN siRNA treated SKRC47 cells. 
 Table of drug concentrations calculated to give a 50% inhibition of growth for cells with 
normal and reduced levels of FLCN protein, Mean ± SD shown. 
SKRC 47 
mean GI50 nM luci 
SiRNA  SD 
meanGI50 nM FLCN 
SiRNA SD 
Echinomycin 2.3 2.3 2.05675 2.39461 
Chromomycin A3  14.0 18.3 7.06925 3.00931 
Vincristine sulfate 9.0 4.4 8.69125 6.97942 
DidemninB B 6.9 7.6 4.14 2.50397 
Doxorubicin  100.0 0.2 186 0.07095 
N,N-
dibenzyldaunomycin 2100.0 2.8 700 0.34699 
 
The data (Fig 12) shows small differences in response to the drugs with regard to FLCN 
expression. These could be indicative of the possibility to identify chemotherapeutic agents 
with the ability to differentiate between FLCN+ and FLCN- cells by this method. The data 
(Table 10) indicate that all drugs tested, except doxorubicin, have higher GI50 values in cells 
with normal FLCN expression compared to the FLCN knockdowns (although in most cases 
this is not statistically significant). The biggest alteration in response due to FLCN knock 
down was a threefold change sensitivity to N,N-dibenzyldaunomycin (experimental planning 
and cell treatment were performed with the kind help of Xiaohong Lu). Building on this 
evidence, we obtained a greater array of compounds for study from Table 9 as highlighted by 
the COMPARE algorithm. 
The range of concentrations tested was considered with regard to these experiments and lower 
concentrations of compound were used for some drugs in other experiments. 
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Drug-induced cytotoxicity in CaKi cells  
In order to establish the best assay system for the identification compounds with differential 
sensitivity with regard to folliculin status, 8 compounds (see table 11) were tested by SRB 
assay in a CaKi-1 Cell system, both with and without knockdown of FLCN Protein by siRNA 
treatment for comparison. The CaKi-1 is a well characterized adherent human epithelial 
kidney clear cell carcinoma cell line originated from a 49-year-old Caucasian male with a 
metastatic site in the skin and established in 1971 (Fogh and Trempe, 1971). CaKi-1s are 
aneuploid cells, with triploid range chromosome counts, but an absent Y chromosome. All 
normal autosomes except chromosome N9 and N19 are represented, often by two or three 
copies. Normal chromosome N5 is and chromosomes N10 and N16 may be over-represented 
with when compered to the copy number of other normal chromosomes. Features of CAKI1 
cell ultrastructural include many microvilli, few filaments, many small mitochondria, well 
developed Golgi and ER, many lipid droplets and multilaminate bodies, secondary lysosomes, 
and no virus particles. (http://www.lgcstandards-atcc.org 17/08/2013) Graphs of the 
comparative dose response curves were generated as before in Luciferase and FLCN siRNA 
treated CaKi-1 cells, after 72 hours of treatment, for the drugs from the mean+/-SD of 5 
replicates from the same day and the GI50 values generated. (Planning and cell treatment with 
the kind help of Xiaohong Lu) 
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Table 11: GI50 values for compounds in CaKi-1 Cells with and without FLCN siRNA knock 
down. 
CAKI1 
GI50 (LUCI 
siRNA) 
GI50  (FLCN 
siRNA) 
doxorubicin (Adriamycin) 0.560 μM 0.65 μM 
N,N-dibenzyldaunomycin 8.1μM 8.8 μM 
mithramycin 422.0 nM 563.0 nM 
phyllanthoside 425.0 nM 771.0 nM 
chromomycin A3 44.0 nM 42.7 nM 
vincristine sulfate 10.4 nM 65.4 nM 
didemnin B 22.8 nM 49.8 nM 
echinomycin 5.7 nM 5.9 nM 
 
Fig 12 illustrates the way cells with different FLCN protein levels react to different chemicals. 
The GI50 values for the compounds are different in these cells compared to the SKRC47 cells 
(Table 11) and the trend for those compounds that do show a difference appears to be one of 
decreased sensitivity (higher GI50) in cells with FLCN knockdown (shown in table3). The 
conclusions that can be drawn from this data are limited due to the incomplete nature of 
siRNA knock down (INTERFERin® can provide around 90% silencing efficiency at 1 nM 
siRNA according to the data sheet [http://www.polyplus-transfection.com]29/08/2013). Its 
inclusion adds useful insight as furthers investigation into the diversity within kidney cancers 
as a group and their reactions to treatment.   
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Fig 12: Graphs and table showing the comparative dose response curves for a selection of 
compounds in CaKi- 1 Cells treated with luciferase SiRNA (FLCN+ve cells) and CaKi1 cells 
treated with FLCN SiRNA to knock down the expression of the protein. 
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Establishing GI50 values for 16 compounds in CaKi-2 cells with and without FLCN 
siRNA knock down. 
Once all compounds from the COMPARE list were obtained, a larger experiment was carried 
out for the 16 compounds listed in Table 12 below (with the GI50s obtained) in CaKi-2 cells 
both with and without knockdown of FLCN Protein by siRNA treatment. It was decided to 
use a different cell line for this experiment.  It was theorized that using a different line may 
provide a better system and would at least increase the breadth of data for the compounds 
already tested. CaKi-2 cells were chosen as they were a long established and well 
characterized line of kidney clear cell carcinoma cells already tested in the lab (unpublished 
data). Caki-2 cells are derived from a sporadic kidney tumour in a 69-year-old male 
Caucasian. Levels of growth inhibition induced by various concentrations of agents were 
measured in both FLCN states, using the sulforhodamine B (SRB) assay, after 72 hours of 
treatment as before, and dose response curves and GI50 values were generated from the mean 
of 5 replicates on the same day. (Planning and cell treatment with the kind help of Xiaohong 
Lu) 
The results are shown in table 12 and Fig 13 below. 
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Table 12: Table of GI50 values for 16 compounds in CaKi-2 cells with and without FLCN siRNA 
knock-down. 
CAKI-2 IC50 siRNA Luci IC50 siRNA FLCN 
bisantrene hydrochloride 0.7 μM 0.97 μM 
doxorubicin  0.70 μM 0.82 μM 
Rapamycin 0.05 μM  5.1 μM 
VM-26 (teniposide) 1.4 μM 1.5 μM 
Menogaril 1.0μM 1.0 μM 
N,N-dibenzyldaunomycin 7.3 μM 7.2 μM 
paclitaxel (Taxol) 46.5nM 22.1 nM 
Mithramycin 202.7nM 93.2 nM 
phyllanthoside 223.8nM 268.1 nM 
chromomycin A3  2.5nM 3.9 nM 
Bruceantin 26.5nM 36.7 nM 
vincristine sulfate 6.1nM 28.6 nM 
didemnin B 4.1 nM 6.8 nM 
morpholino-ADR 21.1 nM 35.4 nM 
cyanomorpholino-ADR  0.5 nM 0.8 nM 
Echinomycin 3.0 nM 5.7 nM 
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Fig 13: Graphs showing the comparative dose response curves for a selection of compounds in 
CaKi- 2 Cells treated with luciferase SiRNA (FLCN+ve cells) and CaKi2 cells treated with 
FLCN SiRNA. 
 
Fig 13 compares the response curves for a selection of compounds with CaKi-2 Cells treated 
with luciferase SiRNA (FLCN+ve cells) and CaKi2 cells treated with FLCN SiRNA.   In 
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these cells, there was no consistent response to siRNA FLCN knockdown on sensitivity to the 
different agents. For many of the compounds the results seem to be showing greater 
sensitivity in the Caki-2 cells with no reduction in FLCN level. This is not what we would 
expect from the predictions of the COMPARE algorithm. However, it is worth noting that 
Mithramycin and Taxol still show the expected reduction in GI50 in FLCN-reduced cells. 
Knockdown of FLCN expression by siRNA in sporadic RCC with wild-type FLCN was 
incomplete (Lu et al. 2011) and so a more suitable model might be to study paired cells in 
which there was no wild-type FLCN expression in one of the pair. Hence comparisons in a 
stable cell system would seem to offer the best opportunity to obtain suitable results on which 
to base sound judgments on the suitability of the drugs as possible treatments for BHD 
tumours. In order to address this issue, a stable cell system was set up where FLCN negative 
cell line was identified and the relevant cells (thyroid metastasis FTC133 cells) were obtained. 
The majority of the final full group of compounds selected after the use of the COMPARE 
algorithm (listed in Table 1with the GI50s obtained) was screened using the SRB growth 
inhibition assay in CaKi- 2 cells (FLCN positive kidney cancer cells described above) and 
FTC133 cells (FLCN negative thyroid metastasis cells) establishing their comparative 
sensitivities to 15 drugs selected from the COMPARE analysis by Xiaohong Lu. The levels of 
growth inhibition induced by various concentrations of agents were measured, using the 
sulforhodamine B (SRB) assay, after 72 hours of treatment with no siRNA treatments and the 
GI50 values calculated in the usual way. Graphs of the comparative dose response curves for 
the selection of compounds in this model showing the mean+/-SD of 5 replicates done on the 
same day are below in Fig 14.  
(Planning and cell treatment with the kind help of Xiaohong Lu) 
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Fig 14: Graphs showing the comparative dose response curves for a selection of compounds in 
CaKi- 2 Cells FLCN+ve and FTC133 FLCN-ve cells. 
 
The promising trend for lower GI50 values in FLCN negative cells does seem to be present for 
the majority of the compounds screened in this experiment, most notably in the case of 
mithramycin- and vincristine-treated cells. This system appeared to give a good indication for 
the suitability of the COMPARE algorithm for choosing prospective drugs and the possibility 
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of identifying a good candidate compound from this selection for further study but it was was 
decided that these cell lines were not strictly comparable due to the differing nature of the 
cells in many aspects other than FLCN status and that this system was unsuitable for drawing 
robust conclusions with regard to the effects of FLCN. (Planning and cell treatment with the 
kind help of Xiaohong Lu) 
While not strictly comparable due to the differing nature of the cells and therefore unsuitable 
for drawing any strong conclusions, I include this experiment as a further investigation and 
illustration of the way different cells react to different chemicals. The FTC133 cells seem to 
show a trend to greater sensitivity to the majority of compounds in this experiment seen from 
comparison of the GI50 values to those of the CAKI cells. This can be clearly seen in Table 13 
below. This could be due to many differences in the cells as they have different genetic 
backgrounds and derive from different tissues (Kidney and thyroid). 
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Table 13; GI50 values for compounds in CaKi-2 Cells and FTC 133 cells taken from the mean of 
5 replicates on the same day. 
72 hour treatment GI50 (CAKI2) GI50 (FTC133) 
bisantrene hydrochloride 3.01 μM 0.44 μM 
doxorubicin  1.004 μM 0.10 μM 
Rapamycin  >10 μM 0.0009 μM 
VM-26 (teniposide) 3.95 μM 0.42 μM 
Menogaril 1.04 μM 0.49 μM 
N,N-dibenzyldaunomycin 33.5456 μM 3.3 μM 
(carboxyphthalato)platinum >100 μM >100 μM 
paclitaxel  72.92575 nM 9.0 nM 
mithramycin 348.8 nM 68.1nM 
phyllanthoside 717.4 nM 63.9 nM 
chromomycin A3  3.9 nM 4.3 nM 
bruceantin 47.9 nM 53.4 nM 
vincristine sulfate 72.6 nM 8.0 nM 
didemnin B 30.9 nM 6.6 nM 
morpholino-ADR 83.2 nM 46.4 nM 
cyanomorpholino-ADR  4.1 nM 2.1 nM 
echinomycin 9.6 nM 4.1nM 
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Compound Screen in FLCN negative UOK-257 Cells and FLCN+ UOK257-2 cells. 
Addressing the need for a robust, stable isogenic FLCN positive and negative pair of cell lines 
to provide a system by which to screen the drugs was a key focus of our initial investigation. 
UOK-257 cells were identified from the literature (Yang et al. 2008, Hong et al. 2010) and 
obtained to form the basis of the main drug screen experiment.  
UOK-257 is the only RCC cell line available that has been derived from a BHD patient with a 
germ line FLCN mutation (a frame shift c.1285dupC). It is predicted to lead to premature 
protein termination, without nonsense-mediated decay (Yang et al., 2008). Growth inhibition 
assays were performed in both UOK-257and UOK-257- 2(Hong et al. 2010) (an isogenic 
FLCN positive stably-transfected cell line) in order to establish their comparative sensitivities 
to the 15 drugs selected from the COMPARE analysis by Xiaohong Lu. The levels of growth 
inhibition induced by various concentrations of agents were measured, using the 
sulphorhodamine B (SRB) assay, after 72 hours of treatment as in the other systems and the 
dose response curves and the GI50 values calculated. The ratio of each UOK-257 GI50 value
 
to 
the corresponding FLCN-expressing GI50 value was then calculated as it mirrors the 
difference in sensitivities to the chemical shown by the two cell lines and therefore the 
selectivity of the drug. These sensitivities are compared in Fig 15 and more detail about the 
data is shown in Table 14. GI50 values were calculated by fitting a sigmoidal 
concentration/inhibition curve to the data obtained from the SRB assays using non-linear least 
square regression (Graph Pad PRISM
TM
). Mean ± SE values are shown in Table 14 with the 
number of the experiments given in brackets. Experiments and analysis were completed with 
the kind help of Xiaohong Lu who designed the experiment and seeded the plates. 
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Fig 15: Screen in UOK-257 cells and UOK FLCN+ cells 
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Table 14: Compound screen in UOK-257 cells and UOK FLCN+ cells 
Compounds 
GI50 nM 
in UOK-257 
GI50 nM 
in UOK-FLCN
+
 
GI50 Ratio 
Of UOK-FLCN
+
/ 
UOK-257 
Mithramycin 64.2 ± 7.9 (3) 634 ± 148 (4) 9.88 
paclitaxel  75.5 ± 9.2 (5) 514 ± 86 (3) 6.81 
Phyllanthoside 199 ± 79 (5) 427 ± 97 (4) 2.15 
Vincristine sulphate 30.1 ± 10.3 (5) 56.4 ± 17.5 (5) 1.88 
doxorubicin  423 ± 54 (3) 581 ± 109 (4) 1.37 
Menogaril 588 ± 57 (4) 757 ± 117 (4) 1.29 
VM-26 (Teniposide) 773 ± 162 (3) 849 ± 358 (3) 1.10 
Morpholino-ADR 0.45 ± 0.03 (3) 0.44 ± 0.10 (3) 0.97 
Chromomycin A3 37.4 ± 6.9 (3) 33.0 ± 5.7 (3) 0.88 
DidemninB B 7.94 ± 1.66 (4) 6.53 ± 1.78 (4) 0.82 
Bisantrene hydrochloride 1753 ± 288 (6) 1345 ± 602 (5) 0.77 
Echinomycin 5.72 ± 0.22 (3) 4.03 ± 0.89 (3) 0.71 
Bruceantin 68.4 ± 14.9 (3) 43.6 ± 5.1 (3) 0.64 
N,N-dibenzyldaunomycin 5739 ± 918 (4) 1273 ± 549 (4) 0.22 
Cyanomophorlino-ADR 3.79 ± 0.39 (3) 0.62 ± 0.16 (3) 0.16 
 
In Table 14 eight chemicals have a ratio greater than 1 showing that these drugs are selective 
for the FLCN negative cell state, having a greater inhibitory affect in UOK-257 cells than in 
UOK-257-FLCN+ cells. The most selective compound was Mithramycin, with an almost 10-
fold difference in the GI50 values of UOK-257 cells (64.2 ± 7.9 nM; n=3) and FLCN
+
 cells 
(634.3 ± 147.9 nM; n=4). Therefore, this compound was selected for further study. 
There were seven compounds in Table 14 with a ratio below one showing that the UOK-257 
cells were less sensitive to these chemicals than the cells that had FLCN expression restored 
and that the FLCN mutant state was being selected for. Cyanomophorlino-ADR showed a 6-
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fold difference in the GI50 values between FLCN
+
 cells (0.62 ± 0.16 nM; n=3) and UOK257-
FLCN
-
 cells (3.79 ± 0.39 nM; n=3) giving the lowest GI50 ratio.  
The data showed considerable differences in the selectivity of the chemicals tested for cells 
with and without FLCN expression, although the compounds were all selected by the 
COMPARE algorithm using the same criteria. 
The data suggest that loss of functional FLCN due to the mutation in UOK-257 cells may lead 
to a greater mithramycin sensitivity measured by these methods. The hypothesis that 
mithramycin preferentially cytotoxic to UOK-257 cells without FLCN expression and is less 
harmful to cells with normal FLCN expression fitted the data obtained. 
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Chapter 4: Results of Further Assessment of Mithramycin  
Mithramycin-induced cytotoxicity in UOK257 cells and UOK257 cells with FLCN 
expression restored.  
Clonogenic assays were carried out to further assess the efficacy of mithramycin with regard 
to possible clinical use in the future and examine whether differences in sensitivity to 
mithramycin between cells expressing FLCN and those not expressing it were reflected in 
differential effects in cell survival and ability to grow, divide and form colonies. After 
exposure to mithramycin at a range of concentrations for 72 hours, followed by the 
subsequent removal of the treatment, UOK257 and UOK257-FLCN
+
 cells were then 
incubated in drug-free medium after the removal of the compound for a further 10 – 15 days 
until colonies formed.  Mithramycin-induced cytotoxicity was then measured by clonogenic 
cell survival as shown in Fig 16. (Planning and cell treatment with the kind help of Xiaohong 
Lu) 
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Fig 16: Clonogenic assays measured mithramycin cytotoxicity in UOK-257FLCN+ cells and 
UOK-257. (Data obtained from 3 experiments and the range of values shown by Error bar).  
(Figure by Xiaohong Lu using my data. Reported in Lu et al., 2011)  
At a concentration of 500 nM of mithramycin, more than 60% of the UOK-257-2-FLCN
+
 
cells survived, while less than 0.1% UOK257-FLCN
-
 cells were able to form colonies. Fewer 
than 8% of cells were observed to be viable in FLCN negative UOK-257 cells, at a 
concentration of 200 nM, in comparison to UOK-257-FLCN
+
 cells in which a cell survival 
Survival  % 100nM 200nM 500nM
UOK257-FLCN- 42 ± 9 (12) 8 ± 2 (12) 0.1 ± 0.1 (11)
UOK257-FLCN+ 106 ± 11 (12) 87 ± 12 (12) 61 ± 17 (12)
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rate of greater than 85% was observed. This is a 10-fold difference between two cell lines. At 
5000 nM, the highest concentration examined, there were still more than 4% FLCN
+
 cells 
surviving and forming colonies.  
The data suggest that loss of functional FLCN due to the mutation in UOK-257 cells may lead 
to a greater mithramycin sensitivity measured by these methods. The hypothesis that 
mithramycin is preferentially cytotoxic to UOK-257 cells without FLCN expression and is 
less harmful to cells with normal FLCN expression fitted the data obtained. 
Such a strong cytotoxic effect and selectivity for the mutant cancer cells over the more normal 
surrounding cells provides a basis for further studies to investigate its possible clinical uses 
BHD associated kidney tumours. 
Mithramycin-induced cytotoxicity in SKRC47cells 
To try and get a broader view of the usefulness of mithramycin as a putative 
chemotherapeutic agent for the treatment of kidney cancers, mithramycin was tested using the 
same protocol as previously discussed for the SRB growth inhibition assay in SKRC47 cells.  
As before the cells were treated with luciferase SiRNA or FLCN SiRNA to investigate any 
FLCN associated changes in this cell line sensitivity to mithramycin. (Planning and cell 
treatment with the kind help of Xiaohong Lu) 
The data obtained for mithramycin shown in Fig 17 in comparison to that of phyllanthoside, 
showed no significant difference between the IG50 for the Luciferase SiRNA treated cells and 
the FLCN SiRNA treated cells. One possible explanation for this could be because the knock 
down was not sufficient to lead to a difference in sensitivity or because there is no FLCN-
dependent difference in sensitivity to mithramycin in this p-articular cell line. The 
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phyllanthoside data appeared to show a trend to increased sensitivity in FLCN positive, 
Luciferase SiRNA Treated cells. 
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Fig 17: Mithramycin-induced cytotoxicity in SKRC47cells 
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Mithramycin-sensitivity in FLCN Negative Cells originating from tumour of non-renal 
origin. Mithramycin-induced Cytotoxicity in FTC133 cells 
To investigate mithramycin-sensitivity in FLCN negative cells originating from cancers of 
non renal origin, a human thyroid carcinoma line, FTC133, was used and SRB growth-
inhibition assays were carried out. The FTC133 cell line is derived from a thyroid metastasis 
that is FLCN-negative. A FLCN-containing construct was introduced into the FTC133 
parental cell line and stably transfected cells were selected. Mithramycin sensitivity was then 
examined in transfected cells with empty vector and low FLCN and high FLCN expression as 
well as in cells transfected with empty vector and therefore no FLCN expression. (with the 
kind help of Xiaohong Lu in planning and preparation) (Transfections were carried out by 
Laurence Seabra).  
 
Fig 18 Mithramycin-induced cytotoxicity in FTC133 cells 
In Fig 18 we compare the mithramycin response in the parental line with that in stably 
transfected lines with differing levels of FLCN expression The trend appears to be the 
opposite to that in the UOK cells, with the higher levels of FLCN appearing possibly to have 
a slightly lower GI50, but these differences are not significant. 
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Mithramycin meanGI.50 (nM) Sd n 
FTC-133parental cells 31.9 34.0 3 
FTC-12empty vector 24.4 30.3 5 
FTC-22low level FLCN 17.3 18.8 3 
FTC-29highlevel FLCN 15.9 16.9 5 
Table 15: Mithramycin-induced cytotoxicity in FTC133 cells. 
Table 15 shows the IG50s of Mithramycin in the 4 differently transfected FTC lines and the 
standard deviations showing that difference in GI50 are not significant. 
Mithramycin sensitivity in VHL positive and negative RCC cell line pairs 
We chose VHL of another gene that gives rise to an inherited kidney cancer syndrome and 
also as an example of a gene commonly mutated in sporadic kidney cancers, as another 
therapeutic target to investigate, to see if the positive indications for the treatment of BHD 
kidney tumors might be applicable to a wider range of diseases and patients. We chose the cell 
lines as there were stable isogenic VHL positive and negative cell pairs that were already 
established and used in the lab. 786-0 cells are a human renal cell adenocarcinoma cell line 
established from a 58-year-old male Caucasian. SKRC45 cells are a human renal cell 
carcinoma cell line. (with the kind help of Xiaohong Lu in planning and preparation) 
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Fig 19: Mithramycin-induced cytotoxicity in VHL positive(WT) and negative(VI) cells 
A small difference in the sensitivity to mithramycin was indicated between 786-0 cells with 
and without VHL but there was no apparent difference in sensitivity to mithramycin seen in 
SKRC45 cells with regard to VHL status (Fig 19). 
Effectiveness of mithramycin in combination with rapamycin 
Facilitated by the FNIP proteins FLCN inactivation in transgenic mice (Hasumi et al., 2008) 
(Baba et al., 2008) and in human cell lines, has been reported to be associated with changes in 
mTOR signalling and energy and/or nutrient sensing. The FLCN-interacting protein, FNIP1, 
interacts with a key negative regulator of mTOR and an important energy-sensing molecule 
5AMP-activated protein kinase (AMPK). AMPK phosphorylates FNIP1 and AMPK 
inhibitors reduced this phosphorylation, resulting in reduced expression of FNIP1.  FLCN 
phosphorylation was also reduced by AMPK inhibitors. Amino acid starvation and rapamycin 
treatment also reduced FLCN phosphorylation facilitated by FNIP1 over-expression, 
suggesting that FLCN may be regulated by mTOR and AMPK signalling. (Baba et al., 2006)  
To investigate the potential involvement of the mTOR (mammalian target of rapamycin) 
signalling pathway in the differential response of cells with regard to FLCN expression a 
rapamycin dose response assay was performed in CaKi-2 cells both with and without 
knockdown of FLCN protein, produced as before by treating control cells with luciferase 
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siRNA and test cells with FLCN SiRNA. The levels of growth inhibition induced by various 
concentrations of rapamycin alone were measured in both cases, using the sulforhodamine B 
assay after 72 hours of treatment as in previous experiments. Fig 20 shows a graph of the 
comparative dose response curves for the mean+/-SD of 5 replicates carried out on the same 
day. The Caki cell/siRNA system, though not ideal, was used for this experiment as it was the 
best system we had at the time, being carried out before the arrival of the FTC and UOK cells. 
(with the kind help of Xiaohong Lu in planning and preparation) 
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Fig 20: Dose response curve for rapamycin in CaKi-2 SiRNA-treated cells 
 
Fig 20 shows that even at relatively high doses the growth inhibition brought about by 
rapamycin alone was modest but did appear to show tendencies to selectivity regarding FLCN 
levels.  
While strong conclusions are best avoided due to the limitations of the experimental system, I 
include this experiment as a further investigation and illustration of the way cells with 
different FLCN protein levels reacted to rapamycin treatment. 
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Western Blot Analyses 
UOK-257 and FLCN positive cells were cultured with a range of concentrations of rapamycin 
for 72 hours. The cells were then collected and lysed. The protein content was then extracted 
and a Western blot analysis was carried out to assess the relative amounts of proteins present. 
The blots are shown in Fig 21 below. 
.  
  
Western Blot Results  
UOK257 cells 
FLCN+cells 
           0,    0.01,   0.1,       1,      10,    100,   1000, 10000 Rapamycin Treatment nM 
FLCN 
FLCN 
pS6 Ribosomal 
pS6 Ribosomal 
Caspase
Caspase 
Fig 21: Western blotting showing levels of protein expression in UOK257 cells with and without 
FLCN expression 
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At a low concentration of rapamycin (1 nM), mTOR activity was shown to be inhibited (as 
measured by S6R phosphorylation) However, only a 10-20% reduction in cell proliferation 
was seen at this concentration (Lu et al 2011) as measured using the sulforhodamine B assay 
after 72 hours of treatment as in previous experiments.  
Further investigation of the potential mechanisms underlying the induced differential 
proliferation effects between the two cell lines included assessment of caspase3activation by 
western analysis also shown in the figure below. There was a markedly higher level of active 
caspase3 in FLCN+ compared to UOK257-FLCN- cells. (with the kind help of Xiaohong Lu 
in planning and preparation) 
Comparison of mithramycin in combination with rapamycin and mithramycin alone, in 
UOK 257 Cells and UOK 257 FLCN+ cells 
To investigate whether the differential mithramycin sensitivity found in UOK257 cells and 
cells with FLCN expression was influenced by inhibition of the mTOR pathway by 
rapamycin, both UOK-257and FLCN
+
 cells were incubated overnight, with 1nM rapamycin in 
the medium or without. Mithramycin was then added at a range of concentrations for 72 hours 
as was done for the previous experiments. Growth inhibition curves and GI50 values were then 
calculated and are compared in Fig 22 and Fig 23, below. (with the kind help of Xiaohong Lu 
in planning and preparation)  
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Fig 22: Comparison of mithramycin alone and in combination with rapamycin in FLCN+ and 
FLCN- cells. 
 
Fig 23: FLCN+ and UOK257 cell growth inhibition in response to exposure of mithramycin in 
combination with 1nM rapamycin and mithramycin alone. Figure by Xiaohong Lu using my 
data (Lu et al., 2011)  
The addition of 1 nM rapamycin can bring about a one-and-a-half-fold increase in sensitivity 
to mithramycin in UOK-257 cells (47 ± 14 nM n=4 for mithramycin and rapamycin, as 
compared to 69 ± 10 nM n=6 for mithramycin alone). This indicates a synergistic effect of the 
90.6 47.3 
746.8 747.2 
0.0
200.0
400.0
600.0
800.0
1000.0
1200.0
Mitramycin GI50 in nM mean 
Mitramycin GI50 in nM
mean
0.1 1 10 100 1000 10000
-150
-100
-50
0
50
100
150
0.1
Mitramycin nM in UOK-257 (72hrs, n 4)
%
 C
o
n
tr
o
l 
(S
R
B
)
. 1 10 100 1000 10000 100000
-150
-100
-50
0
50
100
150
Mitramycin
Mitramycin + 1nM Rapamycin
Mitramycin nM in UOK-FLCN (72hrs, n 4)
A
82 
 
 
 
two drugs in these cells. There was also a very slight (1.1 fold) difference in UOK-257-2 
FLCN
+
 cell growth inhibition induced by the combination of Mithramycin and rapamycin at 
high concentration, this was not as strong as seen in UOK257-FLCN
-
 cells (shown in the 
graphs in fig 23) and did not significantly affect the apparent increase in the selective effect 
against the mutant cancer cells. These results indicate an increased probability that the drug 
treatment may be useful clinically as a possible treatment for BHD associated tumours at 
some point in the future. This evidence also fits with the published reports discussed above 
that show FLCN to be associated with changes in mTOR signaling. 
  
83 
 
 
 
 
Rapamycin’s effect on the effectiveness of mithramycin in cells with and without VHL 
We once again chose to investigate VHL as an example of an inherited kidney cancer 
syndrome and a common change in sporadic kidney cancers, as another possible therapeutic 
target of interest, to see if the positive indications for the treatment of BHD kidney tumours 
might possibly be applied to a wider range of patients and diseases.  
To investigate whether mithramycin sensitivity in VHL-negative cells and cells with VHL 
expression was influenced by inhibition of the mTOR pathway by rapamycin-stable isogenic 
VHL positive and negative cell pairs that were already established and used in the lab were 
chosen. This time 786-0 and SKRC39 cells, a human sporadic renal clear cell carcinoma cell 
line from a primary tumour thought by members of the lab to be a suitably representative cell 
line for this experiment, were chosen. 
Both VHL positive and VHL negative 786-0 and SKRC39 cells were incubated overnight. A 
medium containing 1 nM rapamycin with or without mithramycin was then added at a range 
of concentrations for 72 hours as was done for the previous experiments. Growth inhibition 
curves and GI50 values were then calculated and are compared in Fig 24 and Fig25 below. 
(with the kind help of Xiaohong Lu in planning and preparation) No change in the 
mithramycin sensitivity of 786-0 cells or SKRC39 cells, with or without VHL expression, in 
response to rapamycin treatment, could be detected.   
As the addition of rapamycin to the mithramycin treatment of VHL tumour cells made little to 
no difference to the efficacy of the growth inhibition, from these data the indications are that 
the mTOR pathway is unlikely to be greatly involved in these responses. 
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Fig 24: VHL+(wt) and VHL-(ev) SKRC39 cell growth inhibition in response to exposure of 
Mitramycin in combination with 1nM rapamycin and Mithramycin alone. 
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Fig 25: VHL+(wt) and VHL- 786-0 cell growth inhibition in response to exposure of Mitramycin 
in combination with 1nM rapamycin and Mitramycin alone. 
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Chapter 5: Results of Further Assessment of The Effectiveness of vincristine  
Vincristine also showed a good selectivity in earlier experiments (Fig 15) and of the 
compounds with selectivity for FLCN positive cells it had the lowest GI50 (See table 14). As a 
compound already in use as a chemotherapeutic agent for the treatment of some forms of 
cancer, it’s possible usefulness for use in the case of BHD, kidney cancer and other tumours is 
of considerable interest. 
Vincristine with FTC133 cells 
To investigate vincristine sensitivity in FLCN negative cells originating from cancers of non-
renal origin, the human thyroid carcinoma line FTC133 was used and vincristine sensitivity 
was then examined in stably transfected cells with low FLCN and high FLCN expression as 
well as in cells transfected with empty vector and therefore no FLCN expression. SRB growth 
inhibition assays were carried out as before (Fig 26) 
 (with the kind help of Xiaohong Lu in planning and preparation) 
 
Fig 26: Vincristine-induced cytotoxicity in FTC133 cells 
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Table 15: Vincristine-induced cytotoxicity in FTC133 cells 
 
Vincristine meanGI50 (nM) Sd n 
FTC-12empty vector 8.8 0.8 3 
FTC-22 low level FLCN 3.2 1.6 3 
FTC-2 9high level FLCN 3.2 2.0 5 
 
A possible trend apparently indicating slightly increased sensitivity in FTC-133 cells with 
normal to high FLCN levels to the drug vincristine was seen (Fig 26 and table 15above).  This 
trend differs from the result seen in UOK cell lines and indicates that the lack of FLCN in the 
FTC133 (cells in combination with other factors, unknown, within this cell line) may confer 
some resistance to the cytotoxic effects of vincristine. This once again shows the differences 
between cancer cells and the variability of their responses. 
Comparison of vincristine in combination with rapamycin and vincristine alone, in UOK 
257 Cells and UOK 257 FLCN+ cells. 
To investigate whether the differential vincristine sensitivity found in UOK-257 cells and cells 
with FLCN expression was influenced by inhibition of the mTOR pathway by rapamycin, 
both UOK-257 and FLCN
+
 cells were incubated overnight, with 1nM rapamycin in the 
medium or without. Vincristine was then added at a range of concentrations for 72 hours as 
was done for the previous experiments. (with the kind help of Xiaohong Lu in planning and 
preparation) Growth inhibition curves and GI50 values were then calculated and are compared 
in Fig 27 and Table 16. The addition of Rapamycin appeared to have no significant effect on 
the GI50 of vincristine regardless of the FLCN status of the cells. As no synergistic effect 
could be detected it therefore seems unlikely that the mTOR pathway is involved in the 
selective effects of vincristine in UOK cells with regard to FLCN status. 
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Fig 27: UOK FLCN+ and UOK257 cell growth inhibition in response to exposure of Vincristine 
in combination with 1nM rapamycin and Vincristine alone. 
 
Table 16: UOK FLCN+ and UOK257 cell growth inhibition GI50 values in response to exposure 
of Vincristine in combination with 1nM rapamycin and Vincristine alone. 
  Mean GI50 of 
Vincristine / nM S.D. 
UOK 257 22.8  
16.7 
UOK257 & Rapamycin 20 
            14.9 
UOK 257+FLCN 50.5  
25.4 
UOK257+FLCN &Rapamycin 55.7 
23.3 
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Vincristine sensitivity in VHL positive and negative RCC cell line pairs 
To complete the data on vincristine it was decided that VHL should be investigated as an 
example of another inherited kidney cancer syndrome, and also a common change in sporadic 
kidney cancers, to see if the positive indications for the treatment of BHD kidney tumours 
might be applicable to a wider range of diseases and patients. There were stable isogenic VHL 
positive and negative cell pairs used in the lab that were already established. The same lines 
were used as for the complementary experiments with mithramycin; a 786-0 human renal cell 
adenocarcinoma cell line established from a 58-year-old male Caucasian; and SKRC45 human 
renal cell carcinoma cell line pairs used for the SRB growth inhibition assays for vincristine 
alone(with the kind help of Xiaohong Lu in planning and preparation). Results are shown in 
Fig 28. 
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Fig 28: VHL WT+ and VHL- cell growth inhibition in response to exposure of vincristine alone 
Little difference in growth inhibition could be seen between the VHL positive and VHL 
negative cell types when treated with vincristine. 
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Investigation of the mTOR involvement in vincristine sensitivity in VHL +&- RCCs. 
To investigate whether vincristine sensitivity in VHL negative cells and cells with VHL 
expression could possibly be influenced by changes to the mTOR signalling pathway or have 
any synergistic effect with rapamycin, once again VHL positive and VHL negative 786-0 cells 
were incubated overnight, with or without 1nM rapamycin in the medium. Vincristine was 
then added at a range of concentrations for 72 hours as was done for the previous experiments 
(with the kind help of Xiaohong Lu in planning and preparation). Growth inhibition curves are 
shown below in Fig 29 and Fig 30. 
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Fig 29: 786-O VHL + and 786-O VHL- cell growth inhibition in response to exposure of 
vincristine in combination with 1nM rapamycin and with vincristine alone. 
 
Fig 30: 786-O VHL + and 786-O VHL- cell growth inhibition in response to exposure to 
vincristine in combination with 1nM rapamycin and vincristine alone. 
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The trend of the data indicated very small change in the vincristine sensitivity of 786-0 cells, 
with and without VHL expression, in response to rapamycin treatment.  This is not a 
significant difference but any actual change may possibly be due to the addition of the modest 
growth inhibitory effects of rapamycin to the cytotoxicity of vincristine. 
As the addition of Rapamycin to the vincristine treatment of VHL tumour cells made little to 
no difference to the efficacy of the growth inhibition, from these data the indications are that 
the mTOR pathway is unlikely to be greatly involved in these responses. 
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Chapter 6: Results of Investigations into The Effects of Compound C  
  
Compound C is a known AMPK inhibitor and as such affects the mTOR signalling pathway 
through this inhibition. For this reason its effects were of interest. SRB growth inhibition 
assays were carried out to assess the growth inhibitory capability of compound c in UOK257 
cells with and without FLCN expression (with the kind help of Xiaohong Lu in planning and 
preparation).
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Fig 31: Inhibition of growth, shown by the SRB assay, in UOK-257 cells with and without FLCN 
expression by Compound C. Cells were continuously exposed to the concentrations to the 
chemical for 72 hours. 
  
Fig 31 compared SRB growth inhibition assays and did not appear to show any significant 
difference between FLCN positive and FLCN negative UOK-257 cell lines with regard to 
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Compound C, which showed an appreciable inhibition only at very high doses the IG50 
approximately 1 μM for both cell types tested. 
FLCN positive and FLCN negative UOK-257 cells were incubated overnight, with and 
without 1nM compound C in the medium. Mithramycin was then added at a range of 
concentrations for 72 hours as was done for the previous experiments. Growth inhibition 
curves and GI50 values were then calculated and are compared (with the kind help of 
Xiaohong Lu in planning and preparation). 
SRB growth inhibition assays did not appear to show any great difference between FLCN 
positive and FLCN negative UOK257 cell lines with regard to Compound C. 
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Fig 32: Cell growth inhibition in response to exposure of Mithramycin in combination with 1 nM 
Compound C and Mithramycin alone, for 72 hours, was determined using the SRB assay 
Compound C did not appear to show any sensitising effect on UOK cells, with or without 
FLCN  expression, with regard to inhibition caused by mithramycin treatment (Fig 32). 
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Chapter 7: Slingshot 2 as a synthetic lethal target of FLCN. 
Sling shot (ssh) SiRNA and confocal work,  
These experiments were carried out with the kind help of Xiaohong Lu who helped with the 
transient transfection and gave considerable input into the experimental design.  
The synthetic lethal strategy tries to find those genes that are essential to the cancerous cells 
containing the mutation of interest but not the matched normal cells without the specific cancer 
gene mutation. Hence loss of these genes (referred to as synthetic lethal genes) in the presence of 
the given cancer gene mutation will cause the death of the cancerous cells, but not kill normal 
cells without the mutation. In an attempt to develop new therapeutic treatments for patients 
suffering from Birt–Hogg–Dubé syndrome, we looked for possible interactions which could 
cause synthetic-lethality by knocking down a series of phosphatase proteins in cell lines with 
FLCN inactivation (Lu et al., 2013). 
Initially, Lu searched for potential targets of a synthetic-lethal for FLCN by screening a siRNA 
library of phosphatases. Knock down of Slingshot serine phosphatases SSH2 and SSH3 met the 
criteria for potential positive hits with over two-fold increase in Caspase3/7 activity and decrease 
in cell viability of up to 40% in UOK-257 cells (Lu et al., 2013). 
SSH3 is the third phosphatase of Slingshot family of which there are three members. SSH2 is the 
second. The Slingshot phosphatases have in the past also been shown to have an important role in 
controlling the Cofilin proteins activity. This in turn mediates actin filament disassembly, 
assembly and reorganization within the cell (Mizuno, 2012).  
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I investigated the effects of this SSH2 siRNA knock down by use of clonagenic assays and 
confocal microscopy in collaboration with Xiaohong Lu. I carried out tissue culture, staining 
confocal microscopy and colony counting. Data was jointly analysed.  
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Fig 33: Cell death induced by Sling shot 2 SiRNA treatment of FTC12 cells and FLCN positive 
FTC22cells, as measured by the clonagenic assay. 
Fig 33 shows that Sling shot 2 SiRNA treatment produced cell death in the FTC12 cells and wild 
type FLCN positive cells FTC22 (FTC12 being a FLCN null thyroid cancer cell line and FTC22 
being the same cell line in which wild type FLCN was re-expressed), as measured by the 
clonagenic assay and reveals a significant difference between the survival rates of the two cell 
lines. The absence of FLCN combined with the reduction of SSH2 leads to reduced viability of 
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the cells, when compared to the absence of either one alone. This data indicated that SSH2 is a 
synthetic lethal target for FLCN. 
In Lu et al. 2013 it is also shown that increased Caspase3/7 activation (associated with apoptotic 
cell death) after knockdown of SSH2 by siRNA- appears to be a reaction specific to FLCN-
negative cells such as FTC133-12 cells and UOK-257 cells. It was believed not to be a feature to 
be generally associated with knock down Slingshot gene family (though the effects of SSH2 
knockdown could be enhanced by knockdown of further SSHs).  
p53 mutations are known to be present in both FTC133 cells and UOK-257 cells (Lu et al., 2011) 
suggesting that SSH2 knockdown induced activation of Caspase3/7  may be mediated by a cell 
death pathway independent of p53 (Lu et al., 2013). 
Combinations of SSH1 or SSH3 paired with SSH2, and a combination of all three slingshots 
knockdowns (knockdowns were performed by Xiaohong Lu), showing that the addition of SSH1 
or SSH3 siRNA treatments potentiated the effects of SSH2 knockdown indicating that there 
appeared to be some redundancy between the three slingshot serine phosphatase genes (Lu et al. 
2013).  
The Slingshot proteins have been reported previously to regulate the phosphorylation status of 
Cofilin working antagonistically with the LIM- kinases (Mizuno, 2013). Testis-specific protein 
kinases (TESKS) and LIM-kinases (LIMK) bring about the phosphorylation of Cofilin on a 
specific single serine residue (Ser 3) and this phosphorylated Cofilin (p-Cofilin) is then inactive 
with regard to binding to filamental-actin (F-actin). This inactivation of filamental-actin binding 
then results in the stabilization of F-actin. The Slingshot family phosphatases and PDXP 
(chronophin, pyridoxal phosphate phosphatase) bring about Cofilin reactivation by means of 
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phosphate removal from this specific residue, ser-3. The F-actin is then bound by this Cofilin 
which mediates the severing of F-actin and its depolymerization.  In UOK-257 cell lines, under 
normal physiological conditions, knockdown of phosphatases (SSH/PDXP) would increase 
Cofilin phosphorylation, whereas knockdown of kinases (LIMK/TESK) would result in the 
reduction of Cofilin phosphorylation. 
  
Fig 34: SSH family phosphatase known pathways (Teng et al.2011). 
Only a few regulatory pathways resulting in SSH activation have been ever identified. SSH1L’s 
phosphatase activity is negatively regulated through phosphorylation by PAK4 in some cell 
types, suggesting negative regulation of Rac1 activation on SSH and ADF/cofilin activity. In 
other cell types, SSH is activated through integrin pathway via Rac1 activation. SSH and 
filament-actin colocalization has been reported together with the locatized activation of SSH1L 
(Teng et al.2011), indicating that assembly of F-actin can trigger the local activation of SSH1L 
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and therefore promotes cofilin-mediated actin turnover in protrusive lamellipodia. Scaffolding 
proteins 14-3-3 can also act in modulation of ADF/cofilin-activity by interaction with SSH 
isoforms. Phosphorylation of SSH1L on serines 937 and 978 by protein kinase D (PKD) 
promotes its interaction with 14-3-3 (Teng et al.2011). Fig 34 shows SSH in the regulatory 
pathways modulating cofilin phosphorylation and dephosphorylation. Rho-GTPases are a 
predominant regulator of cofilin phosphatases and kinases. SSH family phosphatise 
dephosphorylate cofilin directly or via LIMK inactivation. Phosphorylated cofilin can no longer 
bind and regulate the F-actin dynamics. Cofilin phosphorylation is mainly regulated by TESK 
and LIMK (Teng et al.2011).  
Effects SSH2 knockdown cofilin phosphorylation and actin. 
This was investigated further with regard to whether or not there might be effects from SSH2 
knockdown, on phosphorylation of Cofilin and its resultant affect on actin organization within the 
cell in FLCN negative cells. To this end confocal micrographs were taken of cells treated with 
siRNA to SSH2 or Cofilin and then stained with phaloidine to fluorescently label the filamental 
actin and DAPI to visualise the nucleus as well as immunofluorescence staining using antibodies 
to either Cofilin or phosphorylated Cofilin. These where bound by alexa 633 labelled secondary 
antibodies. These cell staining were then visualised using the confocal microscope. Each of the 
fluorescent dyes is visualised at a different wave length of light, in one focal plane. This is done 
using a different combination of excitation laser wavelength and detection parameters to give a 
separate image for each protein for the same field of view. The results of these experiments are 
shown in Fig 34 to 43 below.  
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Fig 34: Confocal images showing the effect of treatment with SiRNA to luciferase on Cofilin and F-
actin in UOK-257 cells. 
Cells labled with anti-Cofilin alexa 633 in red (bottom left panel and bottom right merged panel), 
phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and DAPI 
nuclear staining in blue (top right panel and bottom right merged panel) yellow colour in the 
merged panel indicates cofilin and actin colocalization.  This figure shows the distribution of 
cofilin across the cytoplasm and nucleus of these FLCN negative cells and filament-actin in the 
cyto-sceleton.  
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Fig 35: Confocal images showing the effect of treatment with SiRNA to SSH2 on Cofilin and F-actin 
in UOK-257 cells. 
Cells labled with anti-Cofilin alexa 633 in red (bottom left panel and bottom right merged panel), 
phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and DAPI 
nuclear staining in blue (top right panel and bottom right merged panel) yellow colour in the 
merged panel indicates cofilin and actin colocalization. This figure shows the distribution of 
cofilin across the cytoplasm and nucleus showing little reduction, compared to the control. The 
figure also shows filament-actin in the cytoskeleton with little increase compared to the control. 
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Fig 36: Confocal images showing the effect of treatment with SiRNA to Cofilin on Cofilin and F-
actin in UOK-257 cells. 
Cells labled with anti-Cofilin alexa 633 in red (bottom left panel and bottom right merged panel), 
phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and DAPI 
nuclear staining in blue (top right panel and bottom right merged panel) yellow colour in the 
merged panel indicates cofilin and actin colocalization. This figure shows the distribution of 
cofilin across the cytoplasm and nucleus showing a clear reduction the Cofilin Knock Down was 
incomplete. The figure also shows that there is some increase in filament-actin in the 
cytoskeleton, compared to the control. 
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Fig 37: Confocal images showing the effect of treatment with SiRNA to luciferase on P-Cofilin and 
F-actin in UOK-257 cells. 
Cells labeled with anti-P-Cofilin alexa 633 in red (bottom left panel and bottom right merged 
panel), phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and 
DAPI nuclear staining in blue (top right panel and bottom right merged panel).  
 This figure shows the distribution of P-cofilin across the cytoplasm and nucleus of these FLCN 
negative cells and filament-actin in the cytoskeleton. 
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Fig 38: Confocal images showing the effect of treatment with SiRNA to Sling shot 2 on P-Cofilin and 
F-actin in UOK-257 cells.  
Cells labeled with anti-P-Cofilin alexa 633 in red (bottom left panel and bottom right merged 
panel), phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and 
DAPI nuclear staining in blue (top right panel and bottom right merged panel). 
 This figure shows the distribution of P-cofilin across the cytoplasm and nucleus showing little 
reduction, compared to the control. The figure also shows filament-actin in the cytoskeleton with 
no increase compared to the control. 
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Fig 39: Confocal images showing the effect of treatment with SiRNA to Cofilin on P-Cofilin 
and F-actin in UOK-257 cells.  
Cells labeled with anti-P-Cofilin alexa 633 in red (bottom left panel and bottom right merged 
panel), phaloidine F-Actin staining in green (top left panel and bottom right merged panel) and 
DAPI nuclear staining in blue (top right panel and bottom right merged panel). 
 This figure shows the distribution of P-cofilin across the cytoplasm and nucleus showing a clear 
reduction, compared to the control. . The figure also shows filament-actin in the cytoskeleton 
with no increase compared to the control. 
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Fig 40: comparison of the effects of SSH2 and Cofilin SiRNA treatment on Cofilin, phospho-Cofilin 
and actin structure in FLCN negative UOK cells (a compilation of the merged panes of figures 34 to 
39 for comparison. 
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In fig 40 cells are labled with anti-P-Cofilin alexa 633 in, phaloidine F-Actin staining in green 
and DAPI nuclear staining in blue, The yellow colour indicates cofilin and actin colocalization 
(merged panels). 
The images in Fig 40 show that these FLCN-null cells did not seem to exhibit a strong Cofilin 
de/phosphorylation and F-actin regulation response to SSH knockdown and show that these 
FLCN-null cells exhibited no evidence against Cofilin de/phosphorylation disregulation. 
Figure 41 is a repetition of the SSH2 knock down experiment with slightly different laser 
settings.  
It confirmed the observations made previously. Once again the images in Fig 9 show that these 
FLCN-null cells did not seem to exhibit a strong Cofilin de/phosphorylation and F-actin 
regulation response to SSH2 knockdown and show that these FLCN-null cells exhibited no 
evidence against Cofilin de/phosphorylation disregulation. 
In fig 41 below cells are labeled with anti-P-Cofilin alexa 633 in, phaloidine F-Actin staining in 
green and DAPI nuclear staining is shown in blue, the yellow colour indicates cofilin and actin 
colocalization (merged panels). Top left = UOK257cells treated with luciferase control siRNA 
and stained with anti-Cofilin 633. Top right = UOK257cells treated with luciferase control 
siRNA and stained with anti-P-Cofilin 633. Bottomleft = UOK257cells treated with SSH2 siRNA 
and stained with anti-Cofilin 633. Bottom right = UOK257cells treated with SSH2 siRNA and 
stained with anti-P-Cofilin 633. 
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Fig 41: Comparison of the effects of SSH2 treatment on Cofilin, phospho-Cofilin and actin structure 
in UOK-257 cells.  
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In theory knocking down the Slingshot genes with siRNAs, under normal physiological 
conditions, would be expected to give rise to the increase and accumulation of phosphorylated 
Cofilin. This increase could be seen by western analysis in FLCN positive cell lines 
(approximately 400% increase in cofilin phosphorylation), but it was seen to be much smaller in 
the FLCN negative cell line (approximately 150% increase in cofilin phosphorylation), indicating 
the possibility that FLCN is required for the usual phosphatase activity of Slingshot found in 
normal cell conditions (Lu et al., 2013). 
My findings from the confocal microscopy in UOK-257 cells do not disagree with the findings 
stated in Lu et al. (2013), or the suggestion that the absence of FLCN protein in UOK-257 is 
associated with the altered regulation of Cofilin de/phosphorylation pathways. 
Subtle effects on Cofilin phosphorylation from knockdown of SSH2 phosphatase by siRNA 
treatment in cell lines may be seen in the figures above. In normal cells, knockdown of SSH 
phosphatases would increase the phosphorylation of Cofilin, and this increased phospho-Cofilin 
would lead to increased stabilization of filament-actin. In the stainings carried out in UOK-257 
cells without FLCN expression only a slight change in phosphorylation of Cofilin is seen 
following the knock down of SSH2 by siRNA treatment when compared to the luciferase siRNA 
control treatment. This suggested that in UOK-257 FLCN negative cells, there appears to be a 
change to the normal regulation of the phosphorylation and dephosphorylation pathways of 
cofilin which could be associated with the FLCN proteins absence. 
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Fig 42: Top UOK-257 treated with SiRNA to luciferase. Bottom UOK-257 treated with SiRNA to 
SSH2 (phaloidine F-Actin Staining in green and DAPI nuclear staining in blue). 
Fig 42 appears to show a small increase in actin accumulation associated with increased 
Phospho-cofilin, but, while unable to quantify the change per cell, the increase appears more 
likely to be in the region of up to 150%(reported increase for FLCN-ve cells, Lu et al. 2013) than  
400% (reported increase for FLCN+ve cells, Lu et al. 2013). 
The changes in Cofilin phosphorylation and filament-actin are small and subtle. Exactly how 
FLCN may be involved with this is still unknown, as is the possible compensatory regulatory 
Anti-p 
COFIL
111 
 
 
 
mechanism among members of SSH family suggested by observations that SSH2 siRNA-induced 
knockdown was accompanied by increased expression of SSH1 and SSH3, in Lu et al. (2013). 
It was interesting to note when considering possible future therapeutic options and combinations 
thereof, that while it was shown by Lu et al. (2013) that changes to the cell cycle including S and 
G2M shortening, as well as G1 arrest, were brought about by siRNA treatment to knock down 
SSH2 in UOK-257 FLCN-negative cells, the results of the other potential therapy for BHD-RCC 
investigated, mithramycin treatment, showed a pattern change to cell cycle that was quite 
different. The changes induced by mithramycin included increases in both the population and the 
elongation time in G2M cell phase (Lu et al. 2013). 
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Chapter 8: Confocal microscopy to show the distribution of Miz 1 and Myc proteins in cells 
with absent mutated and normal FLCN. 
In order to identify potential novel pathways linked to folliculin function, we decided to examine 
the distribution of FLCN and its putative interactor, the Myc-interacting zinc-finger protein-1 
(MIZ-1), within the cells expressing and not expressing FLCN. MIZ-1 was identified by as a 
putative FLCN-interacting protein by Anne Reiman (unpublished data) working in our lab. After 
yeast two-hybrid analysis had suggested MIZ-1 as a candidate FLCN-interacting protein and co-
immunoprecipitation studies done by Dr. Anne Reiman suggested that this interaction was real 
(see appendix), therefore it was decided to perform colocalization studies to determine if these 
were consistent with this conclusion. 
The function of FLCN is not very well-defined, but the product of the FLCN gene has been 
linked to the regulation of signalling pathways including the AMPK, Transforming growth 
factor- β (TGFβ), mTOR and hypoxia-responsive genes (see Reiman et al, 2012 and references 
within).  
The cytokine TGFβ is known to bring about epithelial cell division arrests by means of switching 
off the proto-oncogene c-myc and further interactions. Its critical cytostatic effects are vital for 
much of the epithelial tissue homeostasis known to happen. TGFβ signal transduction defects 
have been reported in cancers of the pancreas, colon, breast, oral mucosa and other sites. The 
responses to the gene that are implicated in this process are complicated and diverse and how the 
response may be interrelated and mediated remains poorly understood (Seoane et al., 2001). 
113 
 
 
 
 Myc is a known cell growth mediator and heavily involved in proliferation, as well as repression 
and activation of transcription, depending on the nature of the factors associated with it. Both 
Myc messenger RNA and Myc protein are short-lived and c-myc transcriptional down-regulation 
by TGFβ causes depletion of the cells’ Myc protein and its growth-promoting functions in a short 
space of time (Seoane et al., 2001). MIZ-1 was identified as a protein that recognizes certain 
initiator motifs, including core promoters with the sequence 5'-CCCACTCTGC. The amino-
terminal BTB/POZ (BR-C, ttk, bab/ Pox virus, Zinc finger) domain near the N-terminus of a 
fraction of some zinc finger proteins, including in MIZ-1, could possibly mediate 
oligomerization. The central region of MIZ has twelve zinc-finger motifs that are capable of 
initiator motif binding for various Myc-repressed genes. The Myc–MIZ-1 complex has been 
shown to be important in some responses to TGFβ, which would be sufficient to bring about 
rapid changes affecting cell-cycle progression (Seoane et al., 2001). 
The mutated FLCN constructs, 82 (Cys82Ala) and 85 (Cys85Ala) (where Cys in FLCN potential 
metal binding domain had been mutated to Ala by site-directed mutagenesis carried out by 
Uncaar Boora) were transiently transfected into HeLa cells or FTCs to ascertain if, in the 
presence of the mutation, there is still folliculin interaction with MIZ and other proteins. The 
constructs which were expressed were flag tagged FLCN 85 TGC >GCC changing a cystine to an 
alanine, and flag tagged FLCN 82 TGC >GCC changing a cystine to an alanine. We also 
transiently expressed a Flag tagged full length FLCN construct with no mutations, and an empty 
vector control. 
Experiments carried out with the kind help of Dr. Anne Reiman with design and planning. 
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Fig 43: Immunofluoresence staining showing FLCN interaction with MIZ-1 
Cells labeled with anti-FLCN alexa 633 in red (top panel and bottom merged panel), anti-MIZ-1 
alexa 488 staining in green (middle panel and bottom merged panel). The yellow colour indicates 
apparent FLCN and Miz1 proximity and possible colocalization (bottom merged panel). 
 
FLCN 
Miz-1 
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Some evidence of FLCN-MIZ-1 co-localization can be seen in images of immunofluoresence 
staining using anti FLCN alexa 488 seen in green, and anti MIZ alexa 633 seen in red, in HeLa 
cells which are wild type for both proteins, as shown in Fig 43. Upon examination of these 
images, it was decided that the greater resolution of confocal microscopy was needed for the 
accurate visualization of localization and co-localization within individual cultured cells.  
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Fig 44: Top: FTC12 cells stained with anti-MIZ alexa 488 in green and DAPI nuclear stain in blue; 
Bottom: FTC22 cells stained with anti-MIZ alexa 488 in green and DAPI nuclear stain in blue. 
Fig 44 shows that in FLCN negative FTC12 cells, MIZ is present in the nucleus and (in small 
amounts) in the cytoplasm. In the FTC22 cells, this is also the case. However, comparison of the 
two confocal microscopy images shows that the FLCN positive cells appear to show slightly 
more MIZ (although the change could not be quantified) in the Cytoplasm than FLCN negative 
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cells.  This could indicate the possibility that interactions with FLCN may have an effect on MIZ 
distribution. The MIZ protein concentrates in specific areas (nucleoli) within the nucleus.  
MIZ FLCN Interaction in ACHN (ATCC® CRL-1611™) cells. 
We obtained ACHN renal carcinoma cells  and ACHN cells with stable knockdown of FLCN (by 
shRNA) and a stable, scrambled control that were kindly donated by Professor Arnim Pause 
(McGill University, Montreal, Canada) and have been described in Hudon et al. (2010). The 
ACHN cell line was initiated in November 1979 and is derived from a renal cell adenocarcinoma, 
metastatic site: pleural effusion in a 22 year old male Caucasian patient. ACHN cells are FLCN 
positive. These cells are used here as a further example of renal cells with wild type FLCN to 
broaden the study of FLCN. Confocal microscopy of these cells provides clear evidence of a 
MIZ-FLCN interaction, as illustrated in Fig 45 below. 
ACHN3 FLCN positive cells stained with MIZ shown in red and FLCN shown in green and 
DAPI nuclear stain shown in blue. The yellow areas show colocalization of Miz with folliculin 
and indicate likely interaction between the 2 proteins. 
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Fig 45: ACHN3 FLCN positive cells stained with anti-MIZ and anti-FLCN to show possible 
colocalization. 
Anti-MIZ alexa 633 staining shown in red (top right) and anti-FLCN alexa488 in green (top left) 
and DAPI nuclear stain in blue (Top middle). The yellow colour indicates FLCN and Miz1 
proximity and probable colocalization (bottom merged panel). 
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Fig 46 graphical analysis of fig 45 confocal image of ACHN3 FLCN positive cells stained with anti-
MIZ and anti-FLCN to show possible colocalization. 
Anti-MIZ alexa 633 staining shown in red (graph and merged image) and anti-FLCN alexa488 in 
green (graph and merged image). The FLCN and Miz1 proximity and probable colocalization 
indicated by yellow colour in the merged panel and overlapping red and green peaks in the graph. 
The graph shows the intensity of each signal/protein at each point in the cell along the line 
indicated in red in the merged confocal image. 
The graphs showing the analysis of the signal intensity of the 2 wavelengths shows that the peaks 
match closely. While most of the co-localisation occurs within the nucleus it can occur outside 
the nucleus as seen in the cell on the left of the picture above picture (figure 3 and 4) and the right 
of the figure below (figure 47 and 48). 
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Fig 47: Confocal image of ACHN3 FLCN positive cells were stained with anti-MIZ alexa 633 and 
anti-FLCN alexa488 as well as DAPI nuclear stain to show possible colocalization. 
The anti-MIZ alexa 633 staining is shown in red (top right and merged image). The anti-FLCN 
alexa488 is seen in green (top left and merged image) and DAPI nuclear stain in blue (top middle 
and merged image). The FLCN and Miz1 proximity and probable colocalization indicated by 
yellow colour in the merged panel. 
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Fig 48: Graphical analysis of the confocal image of ACHN3 FLCN positive cells were stained with 
anti-MIZ alexa 633 and anti-FLCN alexa488 as well as DAPI nuclear stain to show possible 
colocalization. 
Anti-MIZ alexa 633 staining shown in red (graph and merged image), anti-FLCN alexa488 in 
green (graph and merged image) and DAPI nuclear stain in blue (graph and merged image). The 
FLCN and Miz1 proximity and probable colocalization indicated by yellow colour in the merged 
panel and overlapping red and green peaks in the graph. The graph shows the intensity of each 
signal/protein at each point in the cell along the line indicated in red in the merged confocal 
image. 
Clear evidence of MIZ – FLCN interaction can be seen in Fig 48. The MIZ is mostly in the 
nucleus and the mutant FLCN is in the nucleus and in the cytoplasm. The graphs showing the 
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analysis of the signal intensity of the 2 wavelengths shows that the peaks match closely. The 
inclusion of the DAPI stain in this analysis shows more clearly that while most of the co-
localisation occurs within the nucleus, it can also occur outside the nucleus as seen in the cell 
towards the right which appears as if it may be undergoing cell division. 
We continued our investigation of FLCN and MIZ protein localization with the transient 
transfection of different constructs into FTC12 FLCN negative cells and comparison of the 
different states. 
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Fig 49: FTC 12 cells transiently transfected with construct 82. The cells were later stained 
with anti-Flag alexa 488 and anti-MIZ alexa633 as well as DAPI nuclear stain. 
The anti-MIZ alexa 633 staining is shown in red (top right and merged image). The anti-Flag 
alexa488 is seen in green (top left and merged image) and DAPI nuclear stain in blue (top middle 
and merged image). 
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Fig 49 shows that in FTC12 cells transiently transfected with construct 82 (full length FLCN with 
a Cys82Ala mutation), the mutant FLCN and the MIZ don’t appear to interact in this instance. 
The MIZ is seen as a red punctuate staining and in the corresponding locations there is a lack of 
green alexa 488. The images show no ineraction happening in the cell at the time of fixation. 
 
Fig 50: FTC 12 cells transiently transfected with constructs 82. The cells were later stained with 
anti-Flag alexa 633 and anti-MIZ alexa488 as well as DAPI nuclear stain.  
The anti-Flag alexa 633 staining is shown in red (bottom left and bottom right merged image). 
The anti-MIZ alexa488 is seen in green (top left and merged image) and DAPI nuclear stain in 
blue (top right and merged image). 
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In agreement with Fig49 no evidence of MIZ – FLCN interaction can be seen in Fig 50. The MIZ 
is mostly in the nucleus and the mutant FLCN is mostly in the cytoplasm.  
 
Fig 51: FTC 12 cells which were transiently transfected with constructs 82. The cells were later 
stained with anti-Flag alexa 633 and anti-MIZ alexa488 as well as DAPI nuclear stain. 
The anti-Flag alexa 633 staining is shown in red (bottom left and bottom right merged image). 
The anti-MIZ alexa488 is seen in green (top left and merged image) and DAPI nuclear stain in 
blue (top right and merged image). 
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No evidence of MIZ – FLCN interaction can be seen in this case. The MIZ is mostly in the 
nucleus and the mutant FLCN is mostly in the cytoplasm. 
Figures 49, 50 and 51 demonstrate that there is no evidence of FLCN 82 co-localization with 
MIZ. This does not rule out the possibility of such interaction, but my results suggest that the 
Cys82Ala mutation may affect FLCN/MIz-1 interaction.  
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Fig 52: Top: FTC12 cells stained with anti -MYC alexa 594 in red and DAPI nuclear stain in blue. 
 
Fig 52: Bottom: FTC22 cells stained with anti -MYC alexa 594 in red and DAPI nuclear 
stain in blue. Myc is present in the nucleus and in small amounts in the cytoplasm in both 
FLCN positive and negative FTC cells with little difference to be seen between the two 
states.   
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Fig 53: Merged image of FLCN positive cells stained with anti-FLCN alexa 488 and anti-MYC alexa 
594  
The anti-MYC alexa 594 staining is shown in red (graph and merged image). The anti-FLCN 
alexa488 is seen in green (graph and merged image) and DAPI nuclear stain in blue (graph and 
merged image). 
The graph shows the intensity of each signal/protein at each point in the cell along the line 
indicated in red in the merged confocal image. 
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In Fig 53 the graph shows the relative intensities of green and red signal along the line through 
the image. Green and red peaks at the same point indicate probable proximity of the proteins in 
the cell. This suggests that the proteins are in the same location within the cell and that they may 
interact or possibly be functionally related.   
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Chapter 9: Discussion 
Xiaohong Lu and Wenbin Wei used the COMPARE algorithm to find candidate anticancer 
compounds, tested on the NCI-60 cell line panel, that show preferential cytotoxicity to cell lines 
expressing low levels of active FLCN protein. Fifteen chemicals were selected for their 
differential sensitivity being more effective in cells with low FLCN expression than in cells with 
high FLCN expression. From these compounds, various techniques were used to identify those 
which might impair the viability of a RCC folliculin negative cell line more severely than a wild 
type.  
The main screening method chosen for the screening of the compounds was the SRB growth 
inhibition assay, as it had been used by members of the lab for a substantial period of time and 
had been believed by them to be a robust and cost-effective method of obtaining the information 
needed. 
Initially the choice of cells to be experimented on was difficult, and many of the experiments 
were carried out in systems that were less than ideal. Comparable lines were needed with positive 
and negative FLCN status. These were eventually obtained in the form of the UOK257 cell lines, 
but prior to that, attempts were made to use siRNA knock-downs in FLCN positive RCC cell 
lines.  
We detected differential sensitivity of FLCN negative UOK257 cells over FLCN positive 
UOK257-2 cells for 7 chemicals. Mithramycin was the most notable drug as it showed about a 
10-fold change in the value of the GI50 between FLCN negative UOK257cells and FLCN positive 
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UOK257-2 cells. The compound also produced an increase in cytotoxicity (nearly10-fold more) 
in FLCN negative UOK257cells when compared to FLCN positive UOK257-2 cells (clonogenic 
survival assay, 200 nmol/L), as well as inducing the activity of caspase 3/7 in FLCN negative 
UOK257cells preferentially in a manner that was dose-dependent. Preliminary tests of 
compounds were made in other cell lines, but these systems were not ideal. In the absence of any 
other FLCN negative RCC cell lines, attempts were made to knock down FLCN in FLCN-
containing cells. Each of the lines available at the time in the lab were tested in turn to identify 
the best system. They all offered some insight into the differences in response of different cancer 
cells to drug treatments, but none were satisfactory as the method of transient siRNA knockdown 
was unsuitable for producing a uniform population of FLCN null cells. FTC133 cells were 
obtained which were useful but at the time of the first experiment had no comparable FLCN 
positive line. This problem was later solved by the stable transfection of FLCN into FTC133 
clones for use in the later experiments, which were useful for comparison and gave insight into 
FLCN in non-renal cancers. 
The only RCC cell line that is derived from a patient with BHD available to date is UOK-257, 
and no homozygous FLCN negative sporadic RCC cell lines could be found during the time of 
this study. In wild-type FLCN containing sporadic RCCs (SKRC47 cells and CaKi cells, RCC 
Cell lines with wild type FLCN) knockdown of the expression of FLCN by siRNA , in our hands, 
was not 100% effective, making these models unsuitable for producing comparable findings or 
supporting the work in FLCN negative UOK257cells and FLCN positive UOK257-2 cells. The 
results were hard to interpret and not very robust. Furthermore, this approach did not replicate the 
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situation in BHD syndrome in which inactivation of folliculin is the event which initiates 
tumourigenesis.  
While FTC133 cells are FLCN negative, the fact that they derive from a thyroid metastasis gives 
rise to different properties and behavior. Sensitivity to mithramycin was not seen to correspond to 
the cells’ expression levels for FLCN. Several explanations for this are possible.  
Firstly, co-existing epimutations or mutations in oncogenes or other tumour-suppresor genes may 
alter the response of a cell line which is FLCN-negative to treatment by Mithramycin. Also in the 
thyroid carcinoma FTC-133 cell line FLCN, inactivation may have occurred at a late stage of 
tumourigenesis and as such lead to different functional consequences compared to UOK257 cells 
(BHD RCC), in which FLCN inactivation is an initiating step. 
Thirdly, the cell tissue type may affect the functional consequences of inactivating a tumour 
suppressor gene (e.g. in RCC cell lines, hypoxic induction of HIF-2 expression or VHL 
inactivation induces oncogenic CCND1 expression but in cancer cell lines other than RCCs 
CCND1 expression is not hypoxia-inducible.) The very specific nature of the inherited cancer 
syndrome-associated cancer-susceptibility phenotypes, such as BHD syndrome and VHL disease, 
may possibly be explained in this way. 
Thus, ideally, the experiments in UOK-257 cells would be replicated in additional FLCN-null 
RCC cell lines from BHD patients if they were to become available. 
 
It must be noted that, using a strategy for differentially acting drug candidate identification 
similar to that used by myself and Lu et al. , Sutphin et al. identified 10 chemicals using the 
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COMPARE algorithm that showed differential activity against NCI60 cell lines expressing VHL 
at low and high levels. Of these compounds, four were tested against paired RCC cell lines of 
VHL positive and VHL negative types and it was seen that differential toxicity was shown in 
clonogenic survival studies by Chromomycin A3 (ChA3), to VHL-negative cell lines compared 
to VHL-wild type RCC cell lines.  
 
ChA3 inhibits transcription when it binds in the minor
 
groove of DNA. It is an aureolic acid 
compound, but unlike Mithramycin (also an aureolic acid), no differences between the growth 
inhibitions of ChA3 in UOK-257 FLCN negative cell lines were found when compared to FLCN 
positive cells. GC-rich regions of DNA are bound by Mithramycin which inhibits the gene 
transcription if promoters are rich in GC- residues, and several types of cancer, including 
leukaemia and testicular carcinoma have been treated using Mithramycin (Yuan P et al). Low 
doses of rapamycin (1nM) increased Mithramycin’s selective inhibition of FLCN negative cell 
proliferation. It has been noticed that the presence or absence of wild type p53 in a cell may play 
an important part in Mithramycin-induced cell polyploidy modulation of the death of cells in 
colon carcinoma (Bataller et al). A novel analogue of Mithramycin, Mithramycin SK (MSK), in 
HCT116 cells with wt p53 results in polyploidization and mitotic catastrophe and death by 
necrosis in the majority of cell populations, but early p53-independent apoptosis from G2M block 
was the primary cause of death in HCT-116 (p53-/-)cells. Therefore it may be worth considering 
the possibility that UOK-257 (with p53 gene inactivation) cells’ response to exposure to 
Mithramycin, could also be death by apoptosis when arrested in G2M block involving a p53-
independent pathway. This is supported by Xiaohong Lu’s cell cycle analysis results, which 
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reported that UOK257-FLCN
-
 cells showed an S and G2M phase arrest of the cell cycle in 
response to exposure to Mithramycin. Rapamycin at a low dose (1nM) potentiated Mithramycin 
sensitivity strongly by increasing the tendency to arrest in G2M. In FLCN positive cells, 
Mithramycin induced little G2M cell cycle arrest. 
Caspase 3 (cysteine-aspartic acid protease 3) is the protein which is encoded by the gene CASP3. 
Caspase3 exists in an inactive pro-enzyme form that is processed by proteolytic enzymes to form 
the active Caspase3, which was detected by the antibodies in the blot of the FLCN positive cells. 
Activation of Caspase3 plays a crucial role in bringing about and controlling cell death by 
apoptosis.  
Though the FLCN has been linked to the regulation of a variety of signalling pathways (e.g. the 
hypoxia-responsive genes, mTOR, TGFbeta and AMPK), the function of the FLCN protein is 
still far from fully defined. In order to improve the understanding of its function, other members 
of the lab tested UOK257, FTC 12 and FTC22 cells in gene expression and protein (Kinexus) 
arrays (Reiman et al. 2012). This revealed 5 targets that were expressed differently in all data sets 
dependant on FLCN status. Among these was CASP1 (Caspase 1), which was reduced in FLCN 
negative cells  
Taking into account the importance of CASP1 in apoptosis and our labs data, which showed a 
markedly higher level of active Caspase3 in FLCN
+ 
- compared to UOK257-FLCN
-
 - cells(Lu et 
al.2013), other apoptosis related proteins were investigated, with regard to FLCN expression 
effects. This found increased levels of SMAC/Diablo and HtrA2 in FLCN positive cells (Reiman 
et al 2012).The figure below shows pathways involving SMAC/Diablo and HtrA2 by which 
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further effects may occur. 
 
Fig 54: Apoptosis and survival_FAS signaling cascades  
(Main diagram found from http://pathwaymaps.com/maps/418/  © 2013 Thomson Reuters) 
 
In both sporadic and familial cases it is difficult to treat metastatic kidney cancers. Patients may 
still only be diagnosed after presentation with advanced RCC even though renal imaging is 
offered on an annual basis to enable early RCC detection for patients with BHD syndrome 
Levels affected by FLCN 
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(Menko et al 2009). Some patients may respond to immunotherapy with the cytokines 
interleukin-2 and interferon but this is not frequent. Recently the most frequent management 
strategy has emerged as treatment with therapies (e.g. Sunitinib, Sorafenib, Bevacizumab, etc) to 
targeted HIF downstream targets and the mTOR pathway (e.g. Everolimus Temsirolimus,). These 
agents however are not cytotoxic: while they do prolong life, the identification of targeted 
cytotoxic agents would be a significant advance. Therefore the investigation of Mithramycin as a 
potential treatment for FLCN deficient RCC is of considerable interest.  
After the phosphatase siRNA library screen by Xiaohong Lu in FLCN-null UOK257 cells, 
Slingshot 2 serine phosphatase (SSH2) was identified as a possible synthetic lethal candidate gene 
for FLCN. SSH2 knockdown preferentially induced activation of Caspase3/7 in the FLCN-null 
FTC133-12 thyroid carcinoma cell line and the FLCN-null BHD syndrome UOK257 cell line 
compared with the relevant isogenic FLCN-expressing counterpart line FTC133-22 and 
UOK257-2 respectively.  
By contrast, the other two Slingshot family members SSH1 and SSH3 did not show similar 
patterns as seen with SSH2 when knocked down, although a compensatory regulation mechanism 
in transcripts and proteins was indicated among members of SSH family. Multiple knockdown of 
SSH1 and / or SSH3 potentiated SSH2 siRNA activity in both cell cycle kinetics and induction of 
Caspase3/7 in FLCN-null cells, thus providing indications that Caspase3/7 activation brought 
about by SSH2 knockdown induced siRNA- treatment is not a general Slingshot gene family 
feature, but is an event specific to FLCN-null FTC133-12 and UOK257cells. (Lu et al 2013) 
Having already found Caspase3/7 activity to be induced preferentially in FLCN-deficient 
UOK257 cells following mithramycin treatment it is worth noting that in contrast to SSH2 
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knockdown, no preferential effect was apparent in FLCN-deficient FTC133. It is thought that 
SSH2-knockdown induction of Caspase3/7 activation by is mediated by a cell death pathway that 
is p53-independent, as p53 mutations have been identified in UOK257 and FTC133 cells. 
(UOK257: C.153C>T mutation resulted in an early truncation of P53 protein. FTC133: point 
mutation of P53 gene leaded to inactivation of P53 function by accumulation of the protein.)  
In Lu et al 2013, evidence of cofilin phosphorylation and de-phosphorylation disregulation, or 
differences in folliculin deficient cells, was shown, but this disregulation could be partly 
recovered in FTC133 cells, or fully in UOK257cells, by folliculin replacement as seen in their 
folliculin-expressing counterparts FTC133-22 and UOK257-2. Here I have shown 
immunofluorescent images of these effects in the UOK257 cells, and also evidence of the 
cytotoxic effects as demonstrated by the effect on colony forming ability in FTC133cells.  
The involvement of LIM-kinases and phosphatases of the Slingshot family in filament–actin 
stabilization / activation by cofilin phosphorylation and de/phosphorylation is interesting. Links 
between the function of actin in the cytoskeleton and the function of folliculin had not been seen 
before (Lu et al 2013), where we note that siRNA knockdown SSH1/2 and PDXP phosphatases, 
known regulators for phosphorylation of cofilin, can be associated with reduction in FLCN 
protein expression and transcript of FLCN in the cells examined (data not shown). Inverse 
expression patterns between FLCN and SSH3 proteins and transcripts in UOK257 and ACHN 
cells have been seen (data not shown) which are interesting to note. SSH2 siRNA knockdown 
(and the knock down of other Slingshots) was seen to be accompanied by a reduction in 
expression of FLCN protein, even though no clear relationship was found between basal levels of 
FLCN and SSH2 in the examined cells. The preferential sensitivity to SSH2 knock down by 
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siRNA treatment in folliculin-deficient cells could occur because of the abnormal functioning of 
actin as well as slingshot family disregulation. There is a possibility that the functional 
relationship between SSH2, folliculin and cell death could relate to functions of SSH2 that are 
independent of cofilin. The diverse functions reported for cofilin have included cytochrome c 
release and Bax translocation to mitochondria during excitotoxic neuronal death as well as 
modulation of actin dynamics (Bernsteinet et al 2010, Posadas I et al 2012). 
The heterogeneous groups of disorders that are represented in human cancers are associated with 
tumour suppressor gene inactivation and oncogene activation. The development of targeted 
cancer therapies by targeting the activation of an oncogene is more straightforward, in general, 
than correcting the inactivation of a tumour suppressor gene. A practical approach for novel 
targeted therapy development to improve the management of kidney cancers could be provided 
by this route of synthetic lethal interaction identification (Reinhardt et al 2009, Kaelin et al 2009, 
Kaelin et al 2005), as was shown by the developments for p53 and BRCA1/2 (Reinhardt et al 
2007, Fong et al 2009). 
Finding a synthetic lethal target candidate (SSH2) for cells that lack folliculin suggests that a 
possible option for developing new drugs for BHD syndrome targeted molecularly, and possibly 
for some RCCs of a sporadic nature, could be small molecular weight compounds developed to 
target the activity of SSH2 phosphatase in the future. 
Investigation of the evolutionary conservation patterns of the FLCN sequence  have shown them 
to be consistent with the slow evolution of folliculin protein under a purifying selection which is 
stronger than most genes (Nahorski, et al., 2011). The early part of the gene (the first 230 codons 
approximately) showed the purifying selection and slower evolution more strongly. Non-
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synonymous mutations throughout the protein sequence have been predicted to be potentially 
pathogenic. To date, of the mutations described in  FLCN, more than half have been predicted to 
truncate the protein prematurely (Lim, et al., 2010), but putative pathogenic missense mutations 
were not restricted to specific folliculin protein domains. The pathogenicity of missense 
mutations analyzed seemed to be by means of folliculin stability disruption. These observations 
could be consistent with the hypothesis that folliculin has multiple functions and mutations that 
will compromise multiple aspects of folliculin function result in BHD syndrome. Folliculin 
functions are not well characterized to date. FNIP1 and FNIP2, the two folliculin interacting 
proteins reported, bind to folliculin carboxy-portion (a region beyond codons 516 and 362 
respectively) (Takagi et al., 2008; Baba, et al., 2006). A domain between codons 100 to 230 is 
apparently highly conserved, and this domain might contain folliculin interacting proteins 
binding sites for as-yet unidentified interactors, or could be of great importance for the proteins’ 
structural integrity.  
Using bioinformatic software, an extensive search was performed (Nahorski, et al.), with the aim 
of identifying the folliculin proteins’ structural homologues. A KOG3715 domain was seen to be 
carried in the N-terminus of the folliculin protein which spanned the amino acids around 100-
230. No domain super-family is assigned to the KOG3715 domain and the domain structure has 
not been found to date. Although sequences of distant homologues have been found, the LST7 
(Lethal with Sec thirteen protein 7) protein in Saccharomyces cerevisiae is the only one with an 
annotation. This yeast protein is required for the nitrogen-regulated transport of some amino acid 
permeases from the Golgi to the cell surface (Roberg, et al., 1997). At a size of only 242 amino 
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acids, the LST7 protein is the smallest evolutionarily-functional folliculin protein and is smaller 
than the human folliculin by a large margin.   
A range of missense/IFD (in frame deletion) mutations (p.Phe157del, p.His255Pro, p.Arg239Cys, 
p.Glu510del p.Lys508del and Arg362Cys), were reported to be scattered across the whole 
folliculin protein, with the potential to impair the protein stability in mutated folliculin protein. In 
medical genetics, identifying whether an IFD or missense variant is an unusual polymorphic 
variant or a pathogenic mutation is a recurring obstacle to be overcome. The majority of the 
missense/IFD variants examined in Nahorski, et al., 2011, caused impaired protein stability. In 
unpublished experiments, I investigated the effects of a missense substitution in the amino-
terminal region of folliculin (Cys82Ala), on the ability of folliculin to co-localize with a selection 
of proteins. I showed co-localization with wild type folliculin and Miz and found some 
indications that the Cys82Ala substitution might interfere with the colocalisation of folliculin and 
a candidate interacting protein. This observation is consistent with the hypothesis that amino acid 
residues in the amino-terminal region of folliculin are implicated in folliculin function. 
FLCN is a tumour suppressor gene (Vocke, et al., 2005), and reintroducing the wild-type protein 
into null cells has been shown to bring about tumour inhibition in nude mice xenografts (Hong, et 
al., 2010).   
To date the function of the FLCN protein has not been fully defined. If FLCN is shown to exert 
tumour suppressor activity via a single function then modulation of the relevant pathway might 
represent a promising therapeutic strategy for BHD-related tumours. However, the experiments 
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described here which involve a more unbiased screening approach also provide a strategy to 
developing novel treatments for the disorder.   
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APENDIX 2 
FNIP3: Evidence that the Folliculin tumour suppressor interacts with Miz-1 
Extract from a Summary of Work by Eamonn Maher and Work undertaken by Anne 
Reiman at University of Birmingham, UK. 
 
Folliculin interacts with, and co-localises with, the c-Myc interacting protein Miz-1 
Miz-1 (c-Myc interacting protein) was detected as a potential interacting partner of folliculin in a 
yeast two-hybrid screen using full-length folliculin as a bait against human fetal brain cDNA 
library.  Two independent clones mapping to exons 8-9 of Miz-1 were identified and Miz-1 was 
one of seven potential interactors detected more than once (data not shown). In order to refute or 
confirm this potential interaction FLCN cDNA was amplified from neuroblastoma cell lines and 
cloned into pFLAG-CMV-3 vector. Following immunoprecipitation in Hela cells transiently 
over-expressing both Flag-FLCN and pCDNA-Miz-1, FLCN was shown to co-
immunoprecipitate with Miz-1 in a reciprocal manner. Then HEK293 cells were transiently or 
stably transfected with FLAG-FLCN construct and empty FLAG vector and FLAG beads were 
used for immunoprecipitation. Following immunoprecipitation of FLAG-FLCN and probing with 
anti-Miz-1 antibody, Miz-1 was found to co-immunoprecipitate with folliculin (Figure 1). In 
addition, overexpressed Flag-Folliculin coimmunoprecipitated with endogenous Miz-1. In 
addition pulldown of endogenous folliculin in HEK293 cells coimmunoprecipitated Miz-1. The 
co-immunoprecipitation data were supported by immunofluorescence staining studies that 
demonstrated that Miz-1 and folliculin demonstrated partial and predominately nuclear co-
localisation. 
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Fig.A FLCN interacts with Miz-1 in vitro and in vivo. 
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